<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Diabetol</journal-id><journal-id journal-id-type="pmc-domain-id">107</journal-id><journal-id journal-id-type="pmc-domain">cardiab</journal-id><journal-title-group><journal-title>Cardiovascular Diabetology</journal-title></journal-title-group><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11531181</article-id><article-id pub-id-type="pmcid-ver">PMC11531181.1</article-id><article-id pub-id-type="pmcaid">11531181</article-id><article-id pub-id-type="pmcaiid">11531181</article-id><article-id pub-id-type="pmid">39487482</article-id><article-id pub-id-type="doi">10.1186/s12933-024-02489-4</article-id><article-id pub-id-type="publisher-id">2489</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Oh</surname><given-names initials="R">Rosa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Kim</surname><given-names initials="G">Gyuri</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="KN">Kyu-na</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cho</surname><given-names initials="SH">So Hyun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="JY">Ji Yoon</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="S">Seohyun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="YB">You-Bin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jin</surname><given-names initials="SM">Sang-Man</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hur</surname><given-names initials="KY">Kyu Yeon</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Han</surname><given-names initials="K">Kyungdo</given-names></name><address><email>hkd917@naver.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kim</surname><given-names initials="JH">Jae Hyeon</given-names></name><address><email>jaehyeonmd.kim@samsung.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.264381.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 989X</institution-id><institution>Department of Medicine, Samsung Medical Center, </institution><institution> Sungkyunkwan University School of Medicine, </institution></institution-wrap>81 Irwon-ro, Gangnam-gu, Seoul, 06351 Republic of Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01fpnj063</institution-id><institution-id institution-id-type="GRID">grid.411947.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0470 4224</institution-id><institution>Department of Biomedicine and Health Sciences, College of Medicine, </institution><institution>The Catholic University of Korea, </institution></institution-wrap>Seoul, Republic of Korea </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017xnm587</institution-id><institution-id institution-id-type="GRID">grid.263765.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0533 3568</institution-id><institution>Department of Statistics and Actuarial Science, </institution><institution>Soongsil University, </institution></institution-wrap>369, Sangdo-ro, Dongjak-gu, Seoul, 06978 Republic of Korea </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04q78tk20</institution-id><institution-id institution-id-type="GRID">grid.264381.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 989X</institution-id><institution>Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, </institution><institution>Sungkyunkwan University, </institution></institution-wrap>Seoul, Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>23</volume><issue-id pub-id-type="pmc-issue-id">452478</issue-id><elocation-id>391</elocation-id><history><date date-type="received"><day>22</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>02</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-04 10:25:47.660"><day>04</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12933_2024_Article_2489.pdf"/><abstract id="Abs1"><sec><title>Background and aims</title><p id="Par1">The association between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) is unclear. This study aimed to investigate the impact of spectrum of SLD on the risk of heart failure and cardiovascular (CV) mortality in patients with T2DM.</p></sec><sec><title>Methods</title><p id="Par2">In a nationwide cohort study, 2,745,689 adults with T2DM were followed from 2009 to 2012 until 2018. Participants were categorized into no steatotic liver disease (no SLD) and SLD groups. The SLD group was stratified based on metabolic risk factors, alcohol consumption and viral hepatitis. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for heart failure (HF) and CV mortality risk.</p></sec><sec><title>Results</title><p id="Par3">The prevalence of MASLD, metabolic alcohol-associated liver disease (MetALD), alcohol-associated liver disease with metabolic dysfunction (ALD with MD) and MASLD with viral hepatitis (VH) was 49.6%, 7.2%, 2.3%, and 2.0%. Individuals with MASLD (adjusted HR [aHR], 1.11), MetALD (aHR, 1.14), ALD with MD (aHR, 1.32) and MASLD with VH (aHR, 1.12) had a higher risk of developing HF compared with the no SLD group. The risk of CV mortality was also increased in those with SLD groups compared to those with no SLD. The risk of new-onset HF and CV mortality showed a J-shaped association with alcohol consumption regardless of SLD status.</p></sec><sec><title>Conclusion</title><p id="Par4">SLD is independent risk factor of new-onset HF and CV mortality in persons with T2DM, and alcohol consumption has a J-shaped association with risk of HF and CV mortality, regardless of SLD status.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12933-024-02489-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Steatotic liver disease</kwd><kwd>Heart failure</kwd><kwd>Cardiovascular mortality</kwd><kwd>Type 2 diabetes</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par34">Approximately 462&#160;million individuals are living with type 2 diabetes (T2DM) globally [<xref ref-type="bibr" rid="CR1">1</xref>]. The estimated prevalence of T2DM is supposed to increase from 9.3% in 2019 to 10.9% in 2045 [<xref ref-type="bibr" rid="CR2">2</xref>]. The pathophysiology of T2DM involves pancreatic beta cell dysfunction and insulin resistance [<xref ref-type="bibr" rid="CR3">3</xref>]. Insulin resistance leads to increased levels of free fatty acids, high levels of low-density lipoprotein cholesterol (LDL-C) and impaired nitric oxide production [<xref ref-type="bibr" rid="CR4">4</xref>]. This alteration plays an important role in the development of metabolic disorders including hypertension (HTN), dyslipidemia, and hepatic steatosis [<xref ref-type="bibr" rid="CR4">4</xref>]. Consequently, patients with T2DM tend to have an increased risk of steatotic liver disease (SLD) and cardiovascular (CV) disease [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. </p><p id="Par35">Heart failure (HF) is a common manifestation of CV disease. The prevalence of HF is estimated to be 64&#160;million worldwide [<xref ref-type="bibr" rid="CR7">7</xref>]. A recent systematic review found that patients with HF incur an average of $24,383 in healthcare expenses per year [<xref ref-type="bibr" rid="CR8">8</xref>], compounded by the increasing hospitalization rate for HF [<xref ref-type="bibr" rid="CR9">9</xref>]. It is estimated that 14.9% of patients with T2DM develop HF, and more than half of the deaths in patients with T2DM are attributed to CV disease [<xref ref-type="bibr" rid="CR5">5</xref>]. Therefore, prediction and stratification of CV risk in patients with T2DM are crucial.</p><p id="Par36">The risk of CV disease is influenced by multiple confounding factors, such as the duration of diabetes, glycemic control, alcohol consumption, and comorbidities. A meta-analysis revealed that nonalcoholic fatty liver disease (NAFLD) is a common comorbidity that affects up to 50% of individuals with T2DM [<xref ref-type="bibr" rid="CR6">6</xref>]. Recently, the term NAFLD was replaced by &#8220;metabolic dysfunction-associated steatotic liver disease&#8221; (MASLD) [<xref ref-type="bibr" rid="CR10">10</xref>]. MASLD is defined as hepatic steatosis along with at least one of the five cardio-metabolic risk factors. Both MASLD and T2DM are independent risk factors for CV disease [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. However, despite its clinical significance, research on the relationship among MASLD, HF, and CV death in patients with T2DM remains limited.</p><p id="Par37">Therefore, we investigated the impact of the spectrum of SLD on long-term HF and CV mortality risks in a cohort of patients with T2DM. In addition, we explored the effect of alcohol consumption on the risk of incident HF and CV mortality in individuals with T2DM stratified by their SLD status.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data source</title><p id="Par38">We used data from the National Health Insurance Service (NHIS), a single-payer system that encompasses all citizens of South Korea. The NHIS database contains outpatient and inpatient claims data using the International Classification of Diseases, 10th Edition (ICD-10) codes for prescriptions and medical procedures. In addition, the NHIS database includes results from biennial health-screening examinations, including anthropometric measurements, laboratory results, and self-report questionnaires. Details of the Korean NHIS datasets have been described [<xref ref-type="bibr" rid="CR13">13</xref>]. </p></sec><sec id="Sec4"><title>Study population and study design</title><p id="Par39">We conducted a nationwide cohort study that included 2,745,689 individuals with T2DM aged&#8201;&#8805;&#8201;20 years who underwent a health examination between January 1, 2009, and December 31, 2012. We then excluded individuals with missing data (131,147), a history of liver cancer (C22, V193; <italic toggle="yes">N</italic>&#8201;=&#8201;70,988), liver transplant recipients (Z94.4; <italic toggle="yes">N</italic>&#8201;=&#8201;277), and a history of CV diseases such as myocardial infarction (I21-22; <italic toggle="yes">N</italic>&#8201;=&#8201;104,761), stroke (I63-64; <italic toggle="yes">N</italic>&#8201;=&#8201;242,373), and congestive heart failure (I50; <italic toggle="yes">N</italic>&#8201;=&#8201;90,744). To reduce reverse causality, we also excluded individuals with a diagnosis of HF or who died from any cause within the first year of follow-up (<italic toggle="yes">N</italic>&#8201;=&#8201;17,849). Furthermore, we excluded individuals with co-existing liver disease (<italic toggle="yes">N</italic>&#8201;=&#8201;56,029), leaving a total of 2,031,521 individuals who were followed up until December 31, 2018. A flowchart of the study participants is shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>A Flowchart of the study</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e503" position="float" orientation="portrait" xlink:href="12933_2024_2489_Fig1_HTML.jpg"/></fig></p><p id="Par40">The co-existing liver disease included a variety of conditions, including, drug-induced liver disease (F11-F19;K71), hepatic veno-occlusive disease (I82), liver abscess (K75.0; A06.4), hemochromatosis (E83.1), Wilson&#8217;s disease (E83.0), alpha-1 antitrypsin deficiency (E88.0), autoimmune hepatitis (K75.4), primary biliary cholangitis (K74.3; K74.4), other cholangitis (K83; K83.0&#160;A), and glycogen storage disease (E74). The specific ICD-10 codes are provided in Supplementary Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">No SLD<break/>(789,654)</th><th align="left" colspan="1" rowspan="1">MASLD<break/>(1,008,394)</th><th align="left" colspan="1" rowspan="1">MetALD<break/>(147,192)</th><th align="left" colspan="1" rowspan="1">ALD with MD<break/>(46,369)</th><th align="left" colspan="1" rowspan="1">MASLD with VH<break/>(39,912)</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Age (n [%]) years</td></tr><tr><td align="left" colspan="1" rowspan="1">&lt;&#8201;40</td><td align="left" colspan="1" rowspan="1">65,443 (8.29)</td><td align="left" colspan="1" rowspan="1">96,487 (9.57)</td><td align="left" colspan="1" rowspan="1">17,918 (12.17)</td><td align="left" colspan="1" rowspan="1">4876 (10.52)</td><td align="left" colspan="1" rowspan="1">3011 (7.54)</td></tr><tr><td align="left" colspan="1" rowspan="1">40&#8211;64</td><td align="left" colspan="1" rowspan="1">488,173 (61.82)</td><td align="left" colspan="1" rowspan="1">679,958 (67.43)</td><td align="left" colspan="1" rowspan="1">113,484 (77.1)</td><td align="left" colspan="1" rowspan="1">36,396 (78.49)</td><td align="left" colspan="1" rowspan="1">28,715 (71.95)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;65</td><td align="left" colspan="1" rowspan="1">236,038 (29.89)</td><td align="left" colspan="1" rowspan="1">231,949 (23)</td><td align="left" colspan="1" rowspan="1">15,790 (10.73)</td><td align="left" colspan="1" rowspan="1">5097 (10.99)</td><td align="left" colspan="1" rowspan="1">8186 (20.51)</td></tr><tr><td align="left" colspan="6" rowspan="1">Sex</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">379,079 (48.01)</td><td align="left" colspan="1" rowspan="1">660,111 (65.46)</td><td align="left" colspan="1" rowspan="1">139,993 (95.11)</td><td align="left" colspan="1" rowspan="1">44,834 (96.69)</td><td align="left" colspan="1" rowspan="1">26,190 (65.62)</td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">410,575 (51.99)</td><td align="left" colspan="1" rowspan="1">348,283 (34.54)</td><td align="left" colspan="1" rowspan="1">7199 (4.89)</td><td align="left" colspan="1" rowspan="1">1535 (3.31)</td><td align="left" colspan="1" rowspan="1">13,722 (34.38)</td></tr><tr><td align="left" colspan="1" rowspan="1">Income, Lowest Q1</td><td align="left" colspan="1" rowspan="1">173,693 (22)</td><td align="left" colspan="1" rowspan="1">209,613 (20.79)</td><td align="left" colspan="1" rowspan="1">27,223 (18.49)</td><td align="left" colspan="1" rowspan="1">9176 (19.79)</td><td align="left" colspan="1" rowspan="1">8269 (20.72)</td></tr><tr><td align="left" colspan="6" rowspan="1">Smoking</td></tr><tr><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">516,101 (65.36)</td><td align="left" colspan="1" rowspan="1">521,723 (51.74)</td><td align="left" colspan="1" rowspan="1">27,282 (18.53)</td><td align="left" colspan="1" rowspan="1">8462 (18.25)</td><td align="left" colspan="1" rowspan="1">20,865 (52.28)</td></tr><tr><td align="left" colspan="1" rowspan="1">Former</td><td align="left" colspan="1" rowspan="1">113,092 (14.32)</td><td align="left" colspan="1" rowspan="1">195,502 (19.39)</td><td align="left" colspan="1" rowspan="1">41,134 (27.95)</td><td align="left" colspan="1" rowspan="1">12,634 (27.25)</td><td align="left" colspan="1" rowspan="1">8499 (21.29)</td></tr><tr><td align="left" colspan="1" rowspan="1">Current</td><td align="left" colspan="1" rowspan="1">160,461 (20.32)</td><td align="left" colspan="1" rowspan="1">291,169 (28.87)</td><td align="left" colspan="1" rowspan="1">78,776 (53.52)</td><td align="left" colspan="1" rowspan="1">25,273 (54.5)</td><td align="left" colspan="1" rowspan="1">10,548 (26.43)</td></tr><tr><td align="left" colspan="6" rowspan="1">Drinking</td></tr><tr><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">523,493 (66.29)</td><td align="left" colspan="1" rowspan="1">546,078 (54.15)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">23,774 (59.57)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">225,152 (28.51)</td><td align="left" colspan="1" rowspan="1">462,316 (45.85)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">16,138 (40.43)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">33,428 (4.23)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">147,192 (100)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">7581 (0.96)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">46,369 (100)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Regular exercise (n [%])</td><td align="left" colspan="1" rowspan="1">179,152 (22.69)</td><td align="left" colspan="1" rowspan="1">195,351 (19.37)</td><td align="left" colspan="1" rowspan="1">30,589 (20.78)</td><td align="left" colspan="1" rowspan="1">9706 (20.93)</td><td align="left" colspan="1" rowspan="1">8245 (20.66)</td></tr><tr><td align="left" colspan="1" rowspan="1">AF (n [%])</td><td align="left" colspan="1" rowspan="1">4,412 (0.56)</td><td align="left" colspan="1" rowspan="1">5,821 (0.58)</td><td align="left" colspan="1" rowspan="1">754 (0.51)</td><td align="left" colspan="1" rowspan="1">310 (0.67)</td><td align="left" colspan="1" rowspan="1">333 (0.83)</td></tr><tr><td align="left" colspan="1" rowspan="1">CKD (n [%])</td><td align="left" colspan="1" rowspan="1">76,189 (9.65)</td><td align="left" colspan="1" rowspan="1">97,536 (9.67)</td><td align="left" colspan="1" rowspan="1">7156 (4.86)</td><td align="left" colspan="1" rowspan="1">2073 (4.47)</td><td align="left" colspan="1" rowspan="1">3744 (9.38)</td></tr><tr><td align="left" colspan="1" rowspan="1">CCI score, &#8805;&#8201;5 (n [%])</td><td align="left" colspan="1" rowspan="1">97,715 (12.37)</td><td align="left" colspan="1" rowspan="1">92,263 (9.15)</td><td align="left" colspan="1" rowspan="1">9263 (6.29)</td><td align="left" colspan="1" rowspan="1">3550 (7.66)</td><td align="left" colspan="1" rowspan="1">8755 (21.94)</td></tr><tr><td align="left" colspan="6" rowspan="1">DM duration (n [%])</td></tr><tr><td align="left" colspan="1" rowspan="1">New onset</td><td align="left" colspan="1" rowspan="1">311,252 (39.42)</td><td align="left" colspan="1" rowspan="1">456,749 (45.29)</td><td align="left" colspan="1" rowspan="1">83,021 (56.4)</td><td align="left" colspan="1" rowspan="1">24,617 (53.09)</td><td align="left" colspan="1" rowspan="1">11,067 (27.73)</td></tr><tr><td align="left" colspan="1" rowspan="1">&lt;&#8201;5 years</td><td align="left" colspan="1" rowspan="1">227,454 (28.8)</td><td align="left" colspan="1" rowspan="1">319,946 (31.73)</td><td align="left" colspan="1" rowspan="1">39,557 (26.87)</td><td align="left" colspan="1" rowspan="1">12,970 (27.97)</td><td align="left" colspan="1" rowspan="1">17,974 (45.03)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;5 years</td><td align="left" colspan="1" rowspan="1">250,948 (31.78)</td><td align="left" colspan="1" rowspan="1">231,699 (22.98)</td><td align="left" colspan="1" rowspan="1">24,614 (16.72)</td><td align="left" colspan="1" rowspan="1">8782 (18.94)</td><td align="left" colspan="1" rowspan="1">10,871 (27.24)</td></tr><tr><td align="left" colspan="1" rowspan="1">OHA, &#8805;&#8201;3 (n [%])</td><td align="left" colspan="1" rowspan="1">117,454 (14.87)</td><td align="left" colspan="1" rowspan="1">125,690 (12.46)</td><td align="left" colspan="1" rowspan="1">13,863 (9.42)</td><td align="left" colspan="1" rowspan="1">5142 (11.09)</td><td align="left" colspan="1" rowspan="1">7158 (17.93)</td></tr><tr><td align="left" colspan="1" rowspan="1">Insulin (n [%])</td><td align="left" colspan="1" rowspan="1">68,753 (8.71)</td><td align="left" colspan="1" rowspan="1">58,707 (5.82)</td><td align="left" colspan="1" rowspan="1">5712 (3.88)</td><td align="left" colspan="1" rowspan="1">2244 (4.84)</td><td align="left" colspan="1" rowspan="1">4095 (10.26)</td></tr><tr><td align="left" colspan="1" rowspan="1">Statin (n [%])</td><td align="left" colspan="1" rowspan="1">201,754 (25.55)</td><td align="left" colspan="1" rowspan="1">286,195 (28.38)</td><td align="left" colspan="1" rowspan="1">31,241 (21.22)</td><td align="left" colspan="1" rowspan="1">9595 (20.69)</td><td align="left" colspan="1" rowspan="1">16,500 (41.34)</td></tr><tr><td align="left" colspan="1" rowspan="1">Aspirin (n [%])</td><td align="left" colspan="1" rowspan="1">180,484 (22.86)</td><td align="left" colspan="1" rowspan="1">243,325 (24.13)</td><td align="left" colspan="1" rowspan="1">28,646 (19.46)</td><td align="left" colspan="1" rowspan="1">9131 (19.69)</td><td align="left" colspan="1" rowspan="1">10,829 (27.13)</td></tr><tr><td align="left" colspan="1" rowspan="1">OAC (n [%])</td><td align="left" colspan="1" rowspan="1">2222 (0.28)</td><td align="left" colspan="1" rowspan="1">3133 (0.31)</td><td align="left" colspan="1" rowspan="1">266 (0.18)</td><td align="left" colspan="1" rowspan="1">101 (0.22)</td><td align="left" colspan="1" rowspan="1">132 (0.33)</td></tr><tr><td align="left" colspan="1" rowspan="1">HTN medication</td><td align="left" colspan="1" rowspan="1">268,888 (34.05)</td><td align="left" colspan="1" rowspan="1">422,356 (41.88)</td><td align="left" colspan="1" rowspan="1">53,807 (36.56)</td><td align="left" colspan="1" rowspan="1">16,899 (36.44)</td><td align="left" colspan="1" rowspan="1">22,081 (55.32)</td></tr><tr><td align="left" colspan="1" rowspan="1">Age, years</td><td align="left" colspan="1" rowspan="1">57.23&#8201;&#177;&#8201;12.61</td><td align="left" colspan="1" rowspan="1">55.17&#8201;&#177;&#8201;11.88</td><td align="left" colspan="1" rowspan="1">51.32&#8201;&#177;&#8201;10.42</td><td align="left" colspan="1" rowspan="1">51.73&#8201;&#177;&#8201;10.29</td><td align="left" colspan="1" rowspan="1">55.09&#8201;&#177;&#8201;11.04</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI, kg/m<sup>2</sup></td><td align="left" colspan="1" rowspan="1">22.68&#8201;&#177;&#8201;2.32</td><td align="left" colspan="1" rowspan="1">26.65&#8201;&#177;&#8201;3.11</td><td align="left" colspan="1" rowspan="1">25.93&#8201;&#177;&#8201;3.11</td><td align="left" colspan="1" rowspan="1">25.9&#8201;&#177;&#8201;3.29</td><td align="left" colspan="1" rowspan="1">26.69&#8201;&#177;&#8201;3.12</td></tr><tr><td align="left" colspan="1" rowspan="1">Waist circumference, cm</td><td align="left" colspan="1" rowspan="1">78.64&#8201;&#177;&#8201;6.36</td><td align="left" colspan="1" rowspan="1">89.28&#8201;&#177;&#8201;7.72</td><td align="left" colspan="1" rowspan="1">89.01&#8201;&#177;&#8201;7.43</td><td align="left" colspan="1" rowspan="1">89.33&#8201;&#177;&#8201;7.92</td><td align="left" colspan="1" rowspan="1">89.55&#8201;&#177;&#8201;7.39</td></tr><tr><td align="left" colspan="1" rowspan="1">SBP, mmHg</td><td align="left" colspan="1" rowspan="1">125.55&#8201;&#177;&#8201;15.57</td><td align="left" colspan="1" rowspan="1">130.66&#8201;&#177;&#8201;15.44</td><td align="left" colspan="1" rowspan="1">132.42&#8201;&#177;&#8201;15.55</td><td align="left" colspan="1" rowspan="1">133.12&#8201;&#177;&#8201;16.07</td><td align="left" colspan="1" rowspan="1">129.13&#8201;&#177;&#8201;14.89</td></tr><tr><td align="left" colspan="1" rowspan="1">DBP, mmHg</td><td align="left" colspan="1" rowspan="1">76.59&#8201;&#177;&#8201;9.8</td><td align="left" colspan="1" rowspan="1">80.61&#8201;&#177;&#8201;10.12</td><td align="left" colspan="1" rowspan="1">82.68&#8201;&#177;&#8201;10.39</td><td align="left" colspan="1" rowspan="1">83.02&#8201;&#177;&#8201;10.57</td><td align="left" colspan="1" rowspan="1">79.81&#8201;&#177;&#8201;9.81</td></tr><tr><td align="left" colspan="1" rowspan="1">Fasting glucose, mg/dL</td><td align="left" colspan="1" rowspan="1">141.94&#8201;&#177;&#8201;46.73</td><td align="left" colspan="1" rowspan="1">148.94&#8201;&#177;&#8201;46.9</td><td align="left" colspan="1" rowspan="1">154.15&#8201;&#177;&#8201;46.71</td><td align="left" colspan="1" rowspan="1">157.85&#8201;&#177;&#8201;50.65</td><td align="left" colspan="1" rowspan="1">142.48&#8201;&#177;&#8201;45.98</td></tr><tr><td align="left" colspan="1" rowspan="1">Total cholesterol, mg/dL</td><td align="left" colspan="1" rowspan="1">189.68&#8201;&#177;&#8201;43.04</td><td align="left" colspan="1" rowspan="1">205.79&#8201;&#177;&#8201;45.61</td><td align="left" colspan="1" rowspan="1">205.09&#8201;&#177;&#8201;48.39</td><td align="left" colspan="1" rowspan="1">204.12&#8201;&#177;&#8201;53.54</td><td align="left" colspan="1" rowspan="1">194.28&#8201;&#177;&#8201;41.75</td></tr><tr><td align="left" colspan="1" rowspan="1">HDL-C, mg/dL</td><td align="left" colspan="1" rowspan="1">55.2&#8201;&#177;&#8201;27.89</td><td align="left" colspan="1" rowspan="1">50.23&#8201;&#177;&#8201;29.1</td><td align="left" colspan="1" rowspan="1">53.52&#8201;&#177;&#8201;33.54</td><td align="left" colspan="1" rowspan="1">54.38&#8201;&#177;&#8201;28.53</td><td align="left" colspan="1" rowspan="1">49.41&#8201;&#177;&#8201;21.2</td></tr><tr><td align="left" colspan="1" rowspan="1">LDL-C, mg/dL</td><td align="left" colspan="1" rowspan="1">114&#8201;&#177;&#8201;73.23</td><td align="left" colspan="1" rowspan="1">116.29&#8201;&#177;&#8201;86.33</td><td align="left" colspan="1" rowspan="1">107.14&#8201;&#177;&#8201;125.64</td><td align="left" colspan="1" rowspan="1">104.02&#8201;&#177;&#8201;136.29</td><td align="left" colspan="1" rowspan="1">108.56&#8201;&#177;&#8201;41.36</td></tr><tr><td align="left" colspan="1" rowspan="1">eGFR, mL/min/1.73 m<sup>2</sup></td><td align="left" colspan="1" rowspan="1">86.54&#8201;&#177;&#8201;35.4</td><td align="left" colspan="1" rowspan="1">85.64&#8201;&#177;&#8201;36.32</td><td align="left" colspan="1" rowspan="1">90.62&#8201;&#177;&#8201;38.34</td><td align="left" colspan="1" rowspan="1">92.36&#8201;&#177;&#8201;39.91</td><td align="left" colspan="1" rowspan="1">86.14&#8201;&#177;&#8201;36.76</td></tr><tr><td align="left" colspan="1" rowspan="1">Triglyceride, mg/dL*</td><td align="left" colspan="1" rowspan="1">99.88 (99.78&#8211;99.98)</td><td align="left" colspan="1" rowspan="1">186.66 (186.47-186.84)</td><td align="left" colspan="1" rowspan="1">207.5 (206.9-208.09)</td><td align="left" colspan="1" rowspan="1">212.85 (211.71&#8211;214)</td><td align="left" colspan="1" rowspan="1">164.99 (164.19&#8211;165.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">AST, IU/L*</td><td align="left" colspan="1" rowspan="1">22.2 (22.18&#8211;22.21)</td><td align="left" colspan="1" rowspan="1">28 (27.98&#8211;28.03)</td><td align="left" colspan="1" rowspan="1">32.52 (32.43&#8211;32.6)</td><td align="left" colspan="1" rowspan="1">36.04 (35.85&#8211;36.24)</td><td align="left" colspan="1" rowspan="1">33.17 (32.99&#8211;33.35)</td></tr><tr><td align="left" colspan="1" rowspan="1">ALT, IU/L*</td><td align="left" colspan="1" rowspan="1">19.88 (19.86&#8211;19.9)</td><td align="left" colspan="1" rowspan="1">31.43 (31.4-31.47)</td><td align="left" colspan="1" rowspan="1">33.8 (33.7&#8211;33.9)</td><td align="left" colspan="1" rowspan="1">35.49 (35.29&#8211;35.68)</td><td align="left" colspan="1" rowspan="1">35.81 (35.58&#8211;36.04)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#947;-GTP, IU/L*</td><td align="left" colspan="1" rowspan="1">21.68 (21.65&#8211;21.7)</td><td align="left" colspan="1" rowspan="1">46.76 (46.7-46.83)</td><td align="left" colspan="1" rowspan="1">88.94 (88.59&#8211;89.3)</td><td align="left" colspan="1" rowspan="1">109.38 (108.55-110.22)</td><td align="left" colspan="1" rowspan="1">53.33 (52.93&#8211;53.74)</td></tr></tbody></table><table-wrap-foot><p>SLD, steatotic liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; MetALD, metabolic alcohol-associated liver disease; ALD with MD, alcohol-associated liver disease with metabolic dysfunction; VH, viral hepatitis; AF, atrial fibrillation; CKD, chronic kidney disease; CCI, Charlson comorbidity index; DM, diabetes; OHA, oral hypoglycemic agent; OAC, oral anticoagulant; HTN, hypertension; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density cholesterol; LDL-C, low-density cholesterol; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; &#947;-GTP, gamma-glutamyl-transferase;</p><p>* Geometric mean (95% CI)</p></table-wrap-foot></table-wrap></p><p id="Par41">Individuals with T2DM were classified into five groups based on the Delphi consensus statement [<xref ref-type="bibr" rid="CR10">10</xref>]. The Institutional Review Board of the Samsung Medical Center approved this study (IRB 2024-03-104). Written informed consent was waived because all data was de-identified.</p></sec><sec id="Sec5"><title>Variables</title><p id="Par42">We collected data on demographics (age, sex, income level), lifestyle factors (smoking status, alcohol consumption), medical history (prescriptions, duration of diabetes), anthropometry (height, weight, waist circumference), blood pressure, and blood tests (fasting glucose, total cholesterol, high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl-transferase (&#947;-GTP), LDL-C, estimated glomerular filtration rate (eGFR), triglycerides (TG)). Body mass index (BMI) was calculated as body weight (kg) divided by height (m) squared in meters.</p><p id="Par43">T2DM was defined using two criteria: fasting glucose (FG)&#8201;&#8805;&#8201;126&#160;mg/dL or at least one claim with E11-14 accompanied by a prescription for at least one oral hypoglycemic agent (OHA) or insulin. Individuals with FG&#8201;&#8805;&#8201;126&#160;mg/dL in a health examination and who had not been diagnosed with E11-E14 were classified as new-onset T2DM. Chronic kidney disease (CKD) was defined as an eGFR&#8201;&#8804;&#8201;60 mL/min/1.73&#160;m [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par44">A low-income level was defined as being in the lowest quartile of the NHIS population or receiving government-funded medical aid. The amount of alcohol consumed (g/day) was calculated using a standardized questionnaire. Regular exercise was defined as &#8805;&#8201;3 days/week of vigorous activity at least 20&#160;min/day or &#8805;&#8201;5 days/week of moderate-intensity activity at least 30&#160;min/day. The Charlson Comorbidity Index (CCI) score was defined from at least one claim&#8217;s data in the last 1 year using the ICD-10 code; detailed codes are presented in Supplementary Table 2.</p></sec><sec id="Sec6"><title>Classification of study population</title><p id="Par45">We defined hepatic steatosis using the fatty liver index (FLI) with a cut-off value of &#8805;&#8201;30. FLI was calculated from TG, BMI, &#947;-GTP and waist circumference [<xref ref-type="bibr" rid="CR14">14</xref>]. The FLI with a cut-off value of &#8805;&#8201;30 has been validated in the Korean population with a positive predictive value of 83% for detecting SLD [<xref ref-type="bibr" rid="CR15">15</xref>]. The study population was classified into no SLD (FLI&#8201;&lt;&#8201;30) and SLD groups. The SLD group was subcategorized into MASLD, metabolic alcohol-associated liver disease (MetALD), alcohol-related liver disease (ALD) with metabolic dysfunction (MD) and MASLD with viral hepatitis (VH) group based on alcohol consumption or co-existing liver disease. MASLD was defined as participants with SLD (FLI&#8201;&#8805;&#8201;30) and mild alcohol consumption (&lt;&#8201;30&#160;g/day in male and &lt;&#8201;20&#160;g/day in female) and at least one cardio-metabolic risk factor: obesity (BMI&#8201;&#8805;&#8201;23&#160;kg/m<sup>2</sup> or waist circumference&#8201;&#8805;&#8201;90&#160;cm in males, and &#8805;&#8201;80&#160;cm in female); presence of impaired FG (FG&#8201;&#8805;&#8201;100&#160;mg/dL) or treatment with an OHA or diagnosed with diabetes; HTN (BP&#8201;&#8805;&#8201;130/85 mmHg or treatment with antihypertensive medication); dyslipidemia (TG&#8201;&#8805;&#8201;150&#160;mg/dL or treatment with lipid-lowering medication) and low HDL-C (&#8804;&#8201;40&#160;mg/dL for males and &#8804;&#8201;50&#160;mg/dL for female). The MetALD group included patients with MASLD and heavy alcohol consumption (30&#8211;60&#160;g/day in male and 20&#8211;50&#160;g/day in female). The ALD with MD group was defined as those with MASLD and very heavy alcohol consumption (&#8805;&#8201;60&#160;g/day for male and &#8805;&#8201;50&#160;g/day for female). A separate group was created for individuals with MASLD and VH (B15-19; B00.8; B25.1) to assess the additional effect of VH.</p><p id="Par46">Unlike with MetALD and ALD with MD group, if an individual met the criteria for MASLD but had a prior diagnosis of alcohol abuse (E24.4; F10; G31.2; G62.1; G72.1; I42.6; K29.2; K70; K86.0; Q35.4; R78.0; T51.0; T51.8; T51.9; X65; Y15; Y57.3; Y90; Y91; Z50.2; Z71.4; Z71.2), they were excluded from the MASLD group to ensure that only pure MASLD were identified.</p></sec><sec id="Sec7"><title>Outcomes</title><p id="Par47">The primary outcomes were development of HF and CV death. HF was defined as at least one hospitalization with a diagnosis of I50. CV death was defined as death caused by myocardial infarction (I21-22), stroke (I63-64), or HF (I50).</p><p id="Par48">The secondary outcomes were all-cause mortality and liver-related mortality (K70-76).</p></sec><sec id="Sec25"><title>Sensitivity analysis</title><p id="Par49">To reduce selection bias, we additionally conducted a sensitivity analysis including patients with a history of CV disease. In addition, we conducted competing risk analysis with non-CV mortality to account for the possibility that individuals might die from causes other than CV disease.</p></sec><sec id="Sec26"><title>Statistical analysis</title><p id="Par50">Continuous variables are presented as mean&#8201;&#177;&#8201;standard deviation for normally distributed data, and as mean and 95% confidence intervals (CIs) in non-normally distributed data. Categorical variables are described by frequency and proportion. Baseline characteristics were compared using ANOVA for continuous variables and chi-squared tests for categorical variables. A multivariate Cox proportional hazards regression model was used to assess the risks of HF and CV death. This model estimated the hazard ratios (HRs) and their 95% CIs. Model 1 was a crude model. Model 2 was adjusted for age and sex. Model 3 was further adjusted for income, smoking status, regular exercise, and CCI score. Model 4 was additionally adjusted for BMI, FG level, T2DM duration, insulin use, OHA use, statin use, and CKD.We performed subgroup analyses to assess the potential interactions between the variables and SLD. The study population was further stratified according to alcohol consumption and FLI categories. Statistical analyses were performed using SAS software (version 9.4), and P values&#8201;&lt;&#8201;0.05 were considered statistically significant.</p></sec></sec><sec id="Sec10" sec-type="results"><title>Results</title><sec id="Sec11"><title>Baseline characteristics</title><p id="Par51">Table&#160;<xref rid="Tab1" ref-type="table">1</xref> summarizes the baseline characteristics of our study population (<italic toggle="yes">n</italic>&#8201;=&#8201;2,031,521), categorized into five groups: 789,654 (38.9%) participants with no SLD; 1,008,394 (49.6%) with MASLD; 147,192 (7.2%) with MetALD; 46,369 (2.3%) with ALD with MD and 39,912 (2.0%) with MASLD with VH.</p><p id="Par52">Participants with MetALD or ALD with MD tended to be younger, male, and more likely to be a current smoker. In addition, the MetALD, and ALD with MD groups had higher levels of FG, TG, AST, ALT, and &#947;-GTP and lower LDL-C levels. The MetALD, and ALD with MD groups had lower rates of CKD, CCI sore&#8201;&#8805;&#8201;5, OHA&#8201;&#8805;&#8201;3, insulin use, statin use, aspirin use, and oral anticoagulant (OAC) use.</p><p id="Par53">In contrast, participants without SLD were more likely to be older, female, and have a lower BMI, waist circumference, and blood pressure than those in the SLD group.</p></sec><sec id="Sec12"><title>Risk of HF in different SLD subtypes</title><p id="Par54">Table&#160;<xref rid="Tab2" ref-type="table">2</xref> shows the risk of incident HF and CV mortality according to SLD status. The median follow-up was 7.1 (6.0&#8211;8.1) years for HF and 7.2 (6.1&#8211;8.1) years for CV death. There was a higher risk of developing HF, compared to those with no SLD, for individuals with MASLD (aHR, 1.11; 95% CI, 1.09&#8211;1.13), MetALD (aHR, 1.14; 95% CI, 1.10&#8211;1.17), ALD with MD (aHR, 1.32; 95% CI, 1.26&#8211;1.38) and MASLD with VH (aHR, 1.12; 95%CI, 1.10&#8211;1.17) in model 4.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Risk of HF and CV mortality in different SLD subtypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" rowspan="2" colspan="1"><italic toggle="yes">N</italic></th><th align="left" rowspan="2" colspan="1">Event</th><th align="left" rowspan="2" colspan="1">Duration, PY</th><th align="left" rowspan="2" colspan="1">IR, 1000 PY</th><th align="left" colspan="4" rowspan="1">HR (95% CI)</th></tr><tr><th align="left" colspan="1" rowspan="1">Model 1</th><th align="left" colspan="1" rowspan="1">Model 2</th><th align="left" colspan="1" rowspan="1">Model 3</th><th align="left" colspan="1" rowspan="1">Model 4</th></tr></thead><tbody><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">HF incidence</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">No SLD</td><td align="left" colspan="1" rowspan="1">789,654</td><td align="left" colspan="1" rowspan="1">42,824</td><td align="left" colspan="1" rowspan="1">5400244.7</td><td align="left" colspan="1" rowspan="1">7.93</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">MASLD</td><td align="left" colspan="1" rowspan="1">1,008,394</td><td align="left" colspan="1" rowspan="1">53,929</td><td align="left" colspan="1" rowspan="1">6934888.4</td><td align="left" colspan="1" rowspan="1">7.78</td><td align="left" colspan="1" rowspan="1">0.98 (0.97, 0.99)</td><td align="left" colspan="1" rowspan="1">1.11 (1.09, 1.12)</td><td align="left" colspan="1" rowspan="1">1.11 (1.09, 1.12)</td><td align="left" colspan="1" rowspan="1">1.11 (1.09, 1.13)</td></tr><tr><td align="left" colspan="1" rowspan="1">MetALD</td><td align="left" colspan="1" rowspan="1">147,192</td><td align="left" colspan="1" rowspan="1">6,178</td><td align="left" colspan="1" rowspan="1">1005630.2</td><td align="left" colspan="1" rowspan="1">6.14</td><td align="left" colspan="1" rowspan="1">0.78 (0.76, 0.80)</td><td align="left" colspan="1" rowspan="1">1.15 (1.12, 1.18)</td><td align="left" colspan="1" rowspan="1">1.11 (1.08, 1.14)</td><td align="left" colspan="1" rowspan="1">1.14 (1.10, 1.17)</td></tr><tr><td align="left" colspan="1" rowspan="1">ALD with HD</td><td align="left" colspan="1" rowspan="1">46,369</td><td align="left" colspan="1" rowspan="1">2,338</td><td align="left" colspan="1" rowspan="1">314081.5</td><td align="left" colspan="1" rowspan="1">7.44</td><td align="left" colspan="1" rowspan="1">0.95 (0.91, 0.99)</td><td align="left" colspan="1" rowspan="1">1.36 (1.30, 1.42)</td><td align="left" colspan="1" rowspan="1">1.30 (1.25, 1.36)</td><td align="left" colspan="1" rowspan="1">1.32 (1.26, 1.38)</td></tr><tr><td align="left" colspan="1" rowspan="1">MASLD with VH</td><td align="left" colspan="1" rowspan="1">39,912</td><td align="left" colspan="1" rowspan="1">2,372</td><td align="left" colspan="1" rowspan="1">281896.3</td><td align="left" colspan="1" rowspan="1">8.41</td><td align="left" colspan="1" rowspan="1">1.10 (1.05, 1.14)</td><td align="left" colspan="1" rowspan="1">1.31 (1.25, 1.36)</td><td align="left" colspan="1" rowspan="1">1.12 (1.08, 1.17)</td><td align="left" colspan="1" rowspan="1">1.12 (1.10, 1.17)</td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">CV mortality (I21-22, I50, I63-64)</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">No SLD</td><td align="left" colspan="1" rowspan="1">789,654</td><td align="left" colspan="1" rowspan="1">4,856</td><td align="left" colspan="1" rowspan="1">5476600.7</td><td align="left" colspan="1" rowspan="1">0.89</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">MASLD</td><td align="left" colspan="1" rowspan="1">1,008,394</td><td align="left" colspan="1" rowspan="1">5,119</td><td align="left" colspan="1" rowspan="1">7036275.1</td><td align="left" colspan="1" rowspan="1">0.73</td><td align="left" colspan="1" rowspan="1">0.82 (0.79, 0.85)</td><td align="left" colspan="1" rowspan="1">1.00 (0.96, 1.04)</td><td align="left" colspan="1" rowspan="1">1.00 (0.96, 1.04)</td><td align="left" colspan="1" rowspan="1">1.27 (1.21, 1.33)</td></tr><tr><td align="left" colspan="1" rowspan="1">MetALD</td><td align="left" colspan="1" rowspan="1">147,192</td><td align="left" colspan="1" rowspan="1">507</td><td align="left" colspan="1" rowspan="1">1016575.4</td><td align="left" colspan="1" rowspan="1">0.50</td><td align="left" colspan="1" rowspan="1">0.57 (0.52, 0.62)</td><td align="left" colspan="1" rowspan="1">0.99 (0.90, 1.09)</td><td align="left" colspan="1" rowspan="1">0.91 (0.83, 1.00)</td><td align="left" colspan="1" rowspan="1">1.13 (1.03, 1.25)</td></tr><tr><td align="left" colspan="1" rowspan="1">ALD with MD</td><td align="left" colspan="1" rowspan="1">46,369</td><td align="left" colspan="1" rowspan="1">187</td><td align="left" colspan="1" rowspan="1">318123.8</td><td align="left" colspan="1" rowspan="1">0.59</td><td align="left" colspan="1" rowspan="1">0.67 (0.58, 0.77)</td><td align="left" colspan="1" rowspan="1">1.14 (0.99, 1.32)</td><td align="left" colspan="1" rowspan="1">1.04 (0.90, 1.21)</td><td align="left" colspan="1" rowspan="1">1.25 (1.08, 1.45)</td></tr><tr><td align="left" colspan="1" rowspan="1">MASLD with VH</td><td align="left" colspan="1" rowspan="1">39,912</td><td align="left" colspan="1" rowspan="1">165</td><td align="left" colspan="1" rowspan="1">275931.8</td><td align="left" colspan="1" rowspan="1">0.60</td><td align="left" colspan="1" rowspan="1">0.66 (0.57, 0.77)</td><td align="left" colspan="1" rowspan="1">0.91 (0.78, 1.07)</td><td align="left" colspan="1" rowspan="1">0.88 (0.75, 1.03)</td><td align="left" colspan="1" rowspan="1">1.15 (0.98, 1.35)</td></tr></tbody></table><table-wrap-foot><p>Model 1: Non-Adjusted; Model 2: Age, Sex; Model 3: Age, Sex, Income, Smoking, Regular exercise, CCI Score; Model 4: Age, Sex, Income, Smoking, Regular exercise, CCI Score, Fasting glucose, DM Duration, Insulin, OHA, CKD, Statin, BMI</p><p>IR, incidence rate; PY, person years; HR, hazard ratio; CI, confidence interval; SLD, steatotic liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; MetALD, metabolic alcohol-associated liver disease; ALD with MD, alcohol-associated liver disease with metabolic dysfunction; VH, viral hepatitis; CV, cardiovascular; HF, heart failure;</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>CV mortality risk by SLD subtypes</title><p id="Par55">Individuals with MASLD had a 27% increased risk of CV mortality compared to the no SLD group (aHR,1.27; 95% CI, 1.21&#8211;1.33) Similarly, the risk of CV mortality was increased in MetALD (aHR, 1.13), ALD with MD (aHR, 1.25), although to a lesser extent than the MASLD group. The MASLD with VH groups showed no statistically significant difference with no SLD group.</p></sec><sec id="Sec14"><title>Risk of HF by alcohol consumption and FLI categories</title><p id="Par56">Table&#160;<xref rid="Tab3" ref-type="table">3</xref> presents the risk of incident HF and CV mortality stratified by the FLI and alcohol consumption. Among individuals with FLI&#8201;&lt;&#8201;30, nondrinkers were included in the reference group. In the low-FLI group (FLI&#8201;&lt;&#8201;30), mild alcohol consumption (30&#160;g/day in male and &lt;&#8201;20&#160;g/day in female) was associated with a lower risk of HF (aHR, 0.87; 95% CI, 0.85&#8211;0.89). Conversely, very heavy alcohol consumption (&#8805;&#8201;60&#160;g/day for male and &#8805;&#8201;50&#160;g/day for female) was associated with a higher risk of HF (aHR, 1.16; 95% CI, 1.05&#8211;1.28). This J-shaped trend persisted in the moderate-FLI (FLI 30&#8211;60) and high-FLI (FLI&#8201;&#8805;&#8201;60) groups as displayed in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>. Notably, the risk of new-onset HF increased with higher FLI levels regardless of alcohol consumption.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Risk of HF and CV mortality by alcohol consumption and FLI categories</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">FLI</th><th align="left" rowspan="2" colspan="1">Drinking</th><th align="left" rowspan="2" colspan="1"><italic toggle="yes">N</italic></th><th align="left" rowspan="2" colspan="1">Event</th><th align="left" rowspan="2" colspan="1">Duration, PY</th><th align="left" rowspan="2" colspan="1">IR, 1000 PY</th><th align="left" colspan="4" rowspan="1">HR (95% CI)</th></tr><tr><th align="left" colspan="1" rowspan="1">Model 1</th><th align="left" colspan="1" rowspan="1">Model 2</th><th align="left" colspan="1" rowspan="1">Model 3</th><th align="left" colspan="1" rowspan="1">Model 4</th></tr></thead><tbody><tr><td align="left" colspan="10" rowspan="1"><italic toggle="yes">HF Incidence</italic></td></tr><tr><td align="left" rowspan="4" colspan="1">&lt;&#8201;30</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">523,493</td><td align="left" colspan="1" rowspan="1">32,144</td><td align="left" colspan="1" rowspan="1">3574266.6</td><td align="left" colspan="1" rowspan="1">8.99</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">225,152</td><td align="left" colspan="1" rowspan="1">8,760</td><td align="left" colspan="1" rowspan="1">1548449.6</td><td align="left" colspan="1" rowspan="1">5.66</td><td align="left" colspan="1" rowspan="1">0.63 (0.62, 0.65)</td><td align="left" colspan="1" rowspan="1">0.85 (0.83, 0.87)</td><td align="left" colspan="1" rowspan="1">0.84 (0.82, 0.86)</td><td align="left" colspan="1" rowspan="1">0.87 (0.85, 0.89)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">33,428</td><td align="left" colspan="1" rowspan="1">1,499</td><td align="left" colspan="1" rowspan="1">226631.4</td><td align="left" colspan="1" rowspan="1">6.61</td><td align="left" colspan="1" rowspan="1">0.75 (0.71, 0.79)</td><td align="left" colspan="1" rowspan="1">1.04 (0.98, 1.09)</td><td align="left" colspan="1" rowspan="1">0.98 (0.93, 1.03)</td><td align="left" colspan="1" rowspan="1">1.01 (0.96, 1.07)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">7,581</td><td align="left" colspan="1" rowspan="1">421</td><td align="left" colspan="1" rowspan="1">50897.1</td><td align="left" colspan="1" rowspan="1">8.27</td><td align="left" colspan="1" rowspan="1">0.93 (0.85, 1.03)</td><td align="left" colspan="1" rowspan="1">1.23 (1.12, 1.36)</td><td align="left" colspan="1" rowspan="1">1.14 (1.04, 1.26)</td><td align="left" colspan="1" rowspan="1">1.16 (1.05, 1.28)</td></tr><tr><td align="left" rowspan="4" colspan="1">30&#8211;60</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">359,014</td><td align="left" colspan="1" rowspan="1">23,989</td><td align="left" colspan="1" rowspan="1">2486964.3</td><td align="left" colspan="1" rowspan="1">9.65</td><td align="left" colspan="1" rowspan="1">1.08 (1.06, 1.10)</td><td align="left" colspan="1" rowspan="1">1.10 (1.08, 1.12)</td><td align="left" colspan="1" rowspan="1">1.10 (1.08, 1.12)</td><td align="left" colspan="1" rowspan="1">1.11 (1.10, 1.13)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">234,722</td><td align="left" colspan="1" rowspan="1">9,355</td><td align="left" colspan="1" rowspan="1">1618798.1</td><td align="left" colspan="1" rowspan="1">5.78</td><td align="left" colspan="1" rowspan="1">0.65 (0.64, 0.67)</td><td align="left" colspan="1" rowspan="1">0.89 (0.87, 0.91)</td><td align="left" colspan="1" rowspan="1">0.90 (0.88, 0.93)</td><td align="left" colspan="1" rowspan="1">0.92 (0.90, 0.95)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">55,134</td><td align="left" colspan="1" rowspan="1">2,325</td><td align="left" colspan="1" rowspan="1">376678.0</td><td align="left" colspan="1" rowspan="1">6.17</td><td align="left" colspan="1" rowspan="1">0.69 (0.66, 0.72)</td><td align="left" colspan="1" rowspan="1">0.95 (0.91, 1.00)</td><td align="left" colspan="1" rowspan="1">0.91 (0.87, 0.95)</td><td align="left" colspan="1" rowspan="1">0.97 (0.93, 1.02)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">14,792</td><td align="left" colspan="1" rowspan="1">767</td><td align="left" colspan="1" rowspan="1">100059.2</td><td align="left" colspan="1" rowspan="1">7.67</td><td align="left" colspan="1" rowspan="1">0.86 (0.80, 0.92)</td><td align="left" colspan="1" rowspan="1">1.15 (1.07, 1.23)</td><td align="left" colspan="1" rowspan="1">1.08 (1.00, 1.16)</td><td align="left" colspan="1" rowspan="1">1.13 (1.05, 1.22)</td></tr><tr><td align="left" rowspan="4" colspan="1">&#8805;&#8201;60</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">211,722</td><td align="left" colspan="1" rowspan="1">13,987</td><td align="left" colspan="1" rowspan="1">1452401.0</td><td align="left" colspan="1" rowspan="1">9.63</td><td align="left" colspan="1" rowspan="1">1.09 (1.07, 1.11)</td><td align="left" colspan="1" rowspan="1">1.33 (1.30, 1.35)</td><td align="left" colspan="1" rowspan="1">1.30 (1.30, 1.35)</td><td align="left" colspan="1" rowspan="1">1.34 (1.31, 1.38)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">242,848</td><td align="left" colspan="1" rowspan="1">8,970</td><td align="left" colspan="1" rowspan="1">1658621.3</td><td align="left" colspan="1" rowspan="1">5.41</td><td align="left" colspan="1" rowspan="1">0.62 (0.60, 0.63)</td><td align="left" colspan="1" rowspan="1">1.04 (1.01, 1.07)</td><td align="left" colspan="1" rowspan="1">1.05 (1.02, 1.07)</td><td align="left" colspan="1" rowspan="1">1.08 (1.05, 1.11)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">92,058</td><td align="left" colspan="1" rowspan="1">3,853</td><td align="left" colspan="1" rowspan="1">628952.2</td><td align="left" colspan="1" rowspan="1">6.13</td><td align="left" colspan="1" rowspan="1">0.69 (0.67, 0.71)</td><td align="left" colspan="1" rowspan="1">1.16 (1.12, 1.20)</td><td align="left" colspan="1" rowspan="1">1.10 (1.06, 1.14)</td><td align="left" colspan="1" rowspan="1">1.22 (1.17, 1.26)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">31,577</td><td align="left" colspan="1" rowspan="1">1,571</td><td align="left" colspan="1" rowspan="1">214022.2</td><td align="left" colspan="1" rowspan="1">7.34</td><td align="left" colspan="1" rowspan="1">0.83 (0.79, 0.87)</td><td align="left" colspan="1" rowspan="1">1.34 (1.27, 1.41)</td><td align="left" colspan="1" rowspan="1">1.27 (1.20, 1.33)</td><td align="left" colspan="1" rowspan="1">1.39 (1.31, 1.46)</td></tr><tr><td align="left" colspan="10" rowspan="1"><italic toggle="yes">CV mortality (I21-22, I50, I63-64)</italic></td></tr><tr><td align="left" rowspan="4" colspan="1">&lt;&#8201;30</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">523,493</td><td align="left" colspan="1" rowspan="1">3,729</td><td align="left" colspan="1" rowspan="1">3632122.7</td><td align="left" colspan="1" rowspan="1">1.03</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">225,152</td><td align="left" colspan="1" rowspan="1">926</td><td align="left" colspan="1" rowspan="1">1563761.0</td><td align="left" colspan="1" rowspan="1">0.59</td><td align="left" colspan="1" rowspan="1">0.58 (0.54, 0.62)</td><td align="left" colspan="1" rowspan="1">0.81 (0.75, 0.87)</td><td align="left" colspan="1" rowspan="1">0.77 (0.72, 0.83)</td><td align="left" colspan="1" rowspan="1">0.81 (0.75, 0.87)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">33,428</td><td align="left" colspan="1" rowspan="1">157</td><td align="left" colspan="1" rowspan="1">229140.9</td><td align="left" colspan="1" rowspan="1">0.69</td><td align="left" colspan="1" rowspan="1">0.67 (0.57, 0.79)</td><td align="left" colspan="1" rowspan="1">0.98 (0.83, 1.15)</td><td align="left" colspan="1" rowspan="1">0.84 (0.72, 0.99)</td><td align="left" colspan="1" rowspan="1">0.85 (0.73, 1.01)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">7,581</td><td align="left" colspan="1" rowspan="1">44</td><td align="left" colspan="1" rowspan="1">51576.1</td><td align="left" colspan="1" rowspan="1">0.85</td><td align="left" colspan="1" rowspan="1">0.84 (0.62, 1.13)</td><td align="left" colspan="1" rowspan="1">1.15 (0.85, 1.55)</td><td align="left" colspan="1" rowspan="1">0.97 (0.72, 1.30)</td><td align="left" colspan="1" rowspan="1">0.93 (0.69, 1.26)</td></tr><tr><td align="left" rowspan="4" colspan="1">30&#8211;60</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">359,014</td><td align="left" colspan="1" rowspan="1">2,383</td><td align="left" colspan="1" rowspan="1">2516753.8</td><td align="left" colspan="1" rowspan="1">0.95</td><td align="left" colspan="1" rowspan="1">0.91 (0.86, 0.96)</td><td align="left" colspan="1" rowspan="1">0.94 (0.89, 0.99)</td><td align="left" colspan="1" rowspan="1">0.94 (0.89, 0.99)</td><td align="left" colspan="1" rowspan="1">1.21 (1.14, 1.28)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">234,722</td><td align="left" colspan="1" rowspan="1">897</td><td align="left" colspan="1" rowspan="1">1637401.0</td><td align="left" colspan="1" rowspan="1">0.55</td><td align="left" colspan="1" rowspan="1">0.53 (0.49, 0.57)</td><td align="left" colspan="1" rowspan="1">0.79 (0.73, 0.85)</td><td align="left" colspan="1" rowspan="1">0.75 (0.69, 0.81)</td><td align="left" colspan="1" rowspan="1">0.94 (0.87, 1.02)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">55,134</td><td align="left" colspan="1" rowspan="1">248</td><td align="left" colspan="1" rowspan="1">380674.8</td><td align="left" colspan="1" rowspan="1">0.65</td><td align="left" colspan="1" rowspan="1">0.64 (0.56, 0.73)</td><td align="left" colspan="1" rowspan="1">0.99 (0.87, 1.12)</td><td align="left" colspan="1" rowspan="1">0.87 (0.77, 1.00)</td><td align="left" colspan="1" rowspan="1">1.06 (0.93, 1.21)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">14,792</td><td align="left" colspan="1" rowspan="1">84</td><td align="left" colspan="1" rowspan="1">101357.2</td><td align="left" colspan="1" rowspan="1">0.83</td><td align="left" colspan="1" rowspan="1">0.81 (0.65, 1.01)</td><td align="left" colspan="1" rowspan="1">1.19 (0.96, 1.48)</td><td align="left" colspan="1" rowspan="1">1.04 (0.84, 1.30)</td><td align="left" colspan="1" rowspan="1">1.18 (0.95, 1.47)</td></tr><tr><td align="left" rowspan="4" colspan="1">&#8805;&#8201;60</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">211,722</td><td align="left" colspan="1" rowspan="1">1,283</td><td align="left" colspan="1" rowspan="1">1474920.1</td><td align="left" colspan="1" rowspan="1">0.87</td><td align="left" colspan="1" rowspan="1">0.84 (0.79, 0.89)</td><td align="left" colspan="1" rowspan="1">1.15 (1.08, 1.22)</td><td align="left" colspan="1" rowspan="1">1.14 (1.07, 1.21)</td><td align="left" colspan="1" rowspan="1">1.80 (1.67, 1.95)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">242,848</td><td align="left" colspan="1" rowspan="1">721</td><td align="left" colspan="1" rowspan="1">1683132.0</td><td align="left" colspan="1" rowspan="1">0.43</td><td align="left" colspan="1" rowspan="1">0.42 (0.39, 0.45)</td><td align="left" colspan="1" rowspan="1">0.90 (0.83, 0.98)</td><td align="left" colspan="1" rowspan="1">0.83 (0.76, 0.90)</td><td align="left" colspan="1" rowspan="1">1.24 (1.13, 1.36)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">92,058</td><td align="left" colspan="1" rowspan="1">259</td><td align="left" colspan="1" rowspan="1">635900.6</td><td align="left" colspan="1" rowspan="1">0.41</td><td align="left" colspan="1" rowspan="1">0.40 (0.35, 0.45)</td><td align="left" colspan="1" rowspan="1">0.86 (0.76, 0.98)</td><td align="left" colspan="1" rowspan="1">0.76 (0.67, 0.87)</td><td align="left" colspan="1" rowspan="1">1.10 (0.96, 1.26)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">31,577</td><td align="left" colspan="1" rowspan="1">103</td><td align="left" colspan="1" rowspan="1">216766.6</td><td align="left" colspan="1" rowspan="1">0.48</td><td align="left" colspan="1" rowspan="1">0.47 (0.38, 0.57)</td><td align="left" colspan="1" rowspan="1">0.97 (0.79, 1.18)</td><td align="left" colspan="1" rowspan="1">0.86 (0.70, 1.04)</td><td align="left" colspan="1" rowspan="1">1.19 (0.97, 1.45)</td></tr></tbody></table><table-wrap-foot><p>CV, cardiovascular; FLI, fatty liver index; HF, heart failure; IR incidence rate; PY, person years</p><p>Mild, 30&#160;g/day in male and &lt;&#8201;20&#160;g/day in female; Heavy, 30&#8211;60&#160;g/day in male and 20&#8211;50&#160;g/day in female;, Alcoholic, &#8805;&#8201;60&#160;g/day for male and &#8805;&#8201;50&#160;g/day for female</p></table-wrap-foot></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Risk of HF and CV mortality by alcohol consumption and FLI</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1945" position="float" orientation="portrait" xlink:href="12933_2024_2489_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec15"><title>Risk of CV mortality by alcohol consumption and FLI categories</title><p id="Par57">Table&#160;<xref rid="Tab3" ref-type="table">3</xref> shows an association between increasing FLI levels and higher CV mortality regardless of alcohol consumption. When plotting the relationship between FLI and the risk of HF, CV mortality, it showed a linear association presented to Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>. This trend was particularly pronounced in non-alcohol group, where the risk of CV mortality progressively increased with higher FLI (FLI 30&#8211;60: aHR, 1.21; 95% CI, 1.14&#8211;1.28; FLI&#8201;&#8805;&#8201;60: aHR, 1.80; 95% CI, 1.67&#8211;1.95).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Linear relationship between high FLI and increased risk of HF and CV mortality</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1962" position="float" orientation="portrait" xlink:href="12933_2024_2489_Fig3_HTML.jpg"/></fig></p><p id="Par58">However, mild drinkers (30&#160;g/day in male and &lt;&#8201;20&#160;g/day in female) tended to have a lower risk of CV mortality than non-alcohol group. Even after excluding participants with VH, the results remained unchanged (Supplementary Table 3).</p></sec><sec id="Sec16"><title>Risk of all-cause and liver-related mortality by SLD subtypes</title><p id="Par59">Regarding all-cause and liver-related mortality, all subtype of SLD groups showed increased risk compared to no SLD group. (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>) In addition, MetALD and ALD with MD group showed more increased risk compared to MASLD. Interestingly, viral hepatitis showed additional impact on all-cause and liver-related mortality.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Risk of all-cause and liver-related mortality in different SLD subtypes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" rowspan="2" colspan="1"><italic toggle="yes">N</italic></th><th align="left" rowspan="2" colspan="1">Event</th><th align="left" rowspan="2" colspan="1">Duration, PY</th><th align="left" rowspan="2" colspan="1">IR, 1000 PY</th><th align="left" colspan="4" rowspan="1">HR (95% C.I)</th></tr><tr><th align="left" colspan="1" rowspan="1">Model 1</th><th align="left" colspan="1" rowspan="1">Model 2</th><th align="left" colspan="1" rowspan="1">Model 3</th><th align="left" colspan="1" rowspan="1">Model 4</th></tr></thead><tbody><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">All-cause mortality</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">No SLD</td><td align="left" colspan="1" rowspan="1">789,654</td><td align="left" colspan="1" rowspan="1">65,943</td><td align="left" colspan="1" rowspan="1">5476600.7</td><td align="left" colspan="1" rowspan="1">12.04</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">MASLD</td><td align="left" colspan="1" rowspan="1">1,008,394</td><td align="left" colspan="1" rowspan="1">64,148</td><td align="left" colspan="1" rowspan="1">7036275.1</td><td align="left" colspan="1" rowspan="1">9.12</td><td align="left" colspan="1" rowspan="1">0.76 (0.75, 0.77)</td><td align="left" colspan="1" rowspan="1">0.87 (0.86, 0.88)</td><td align="left" colspan="1" rowspan="1">0.87 (0.87, 0.88)</td><td align="left" colspan="1" rowspan="1">1.21 (1.20, 1.23)</td></tr><tr><td align="left" colspan="1" rowspan="1">MetALD</td><td align="left" colspan="1" rowspan="1">147,192</td><td align="left" colspan="1" rowspan="1">9,479</td><td align="left" colspan="1" rowspan="1">1016575.4</td><td align="left" colspan="1" rowspan="1">9.32</td><td align="left" colspan="1" rowspan="1">0.78 (0.77, 0.80)</td><td align="left" colspan="1" rowspan="1">1.12 (1.10, 1.15)</td><td align="left" colspan="1" rowspan="1">1.06 (1.04, 1.09)</td><td align="left" colspan="1" rowspan="1">1.40 (1.37, 1.43)</td></tr><tr><td align="left" colspan="1" rowspan="1">ALD with MD</td><td align="left" colspan="1" rowspan="1">46,369</td><td align="left" colspan="1" rowspan="1">4,033</td><td align="left" colspan="1" rowspan="1">318123.8</td><td align="left" colspan="1" rowspan="1">12.68</td><td align="left" colspan="1" rowspan="1">1.06 (1.03, 1.10)</td><td align="left" colspan="1" rowspan="1">1.48 (1.44, 1.53)</td><td align="left" colspan="1" rowspan="1">1.39 (1.35, 1.43)</td><td align="left" colspan="1" rowspan="1">1.77 (1.72, 1.83)</td></tr><tr><td align="left" colspan="1" rowspan="1">MASLD with VH</td><td align="left" colspan="1" rowspan="1">39,912</td><td align="left" colspan="1" rowspan="1">3,393</td><td align="left" colspan="1" rowspan="1">275931.8</td><td align="left" colspan="1" rowspan="1">12.30</td><td align="left" colspan="1" rowspan="1">1.02 (0.99, 1.06)</td><td align="left" colspan="1" rowspan="1">1.28 (1.24, 1.33)</td><td align="left" colspan="1" rowspan="1">1.16 (1.12, 1.20)</td><td align="left" colspan="1" rowspan="1">1.62 (1.57, 1.68)</td></tr><tr><td align="left" colspan="9" rowspan="1"><italic toggle="yes">Liver-related mortality</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">No SLD</td><td align="left" colspan="1" rowspan="1">789,654</td><td align="left" colspan="1" rowspan="1">845</td><td align="left" colspan="1" rowspan="1">5476600.7</td><td align="left" colspan="1" rowspan="1">0.15</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">MASLD</td><td align="left" colspan="1" rowspan="1">1,008,394</td><td align="left" colspan="1" rowspan="1">1,621</td><td align="left" colspan="1" rowspan="1">7036275.1</td><td align="left" colspan="1" rowspan="1">0.23</td><td align="left" colspan="1" rowspan="1">1.50 (1.38, 1.63)</td><td align="left" colspan="1" rowspan="1">1.43 (1.31, 1.55)</td><td align="left" colspan="1" rowspan="1">1.44 (1.33, 1.57)</td><td align="left" colspan="1" rowspan="1">3.71 (3.38, 4.08)</td></tr><tr><td align="left" colspan="1" rowspan="1">MetALD</td><td align="left" colspan="1" rowspan="1">147,192</td><td align="left" colspan="1" rowspan="1">860</td><td align="left" colspan="1" rowspan="1">1016575.4</td><td align="left" colspan="1" rowspan="1">0.85</td><td align="left" colspan="1" rowspan="1">5.52 (5.02, 6.10)</td><td align="left" colspan="1" rowspan="1">4.81 (4.36, 5.31)</td><td align="left" colspan="1" rowspan="1">4.48 (4.05, 4.95)</td><td align="left" colspan="1" rowspan="1">9.62 (8.66, 10.69)</td></tr><tr><td align="left" colspan="1" rowspan="1">ALD with MD</td><td align="left" colspan="1" rowspan="1">46,369</td><td align="left" colspan="1" rowspan="1">536</td><td align="left" colspan="1" rowspan="1">318123.8</td><td align="left" colspan="1" rowspan="1">1.68</td><td align="left" colspan="1" rowspan="1">11.00 (9.87, 12.25)</td><td align="left" colspan="1" rowspan="1">9.36 (8.36, 10.46)</td><td align="left" colspan="1" rowspan="1">8.52 (7.61, 9.53)</td><td align="left" colspan="1" rowspan="1">17.22 (15.32, 19.35)</td></tr><tr><td align="left" colspan="1" rowspan="1">MASLD with VH</td><td align="left" colspan="1" rowspan="1">39,912</td><td align="left" colspan="1" rowspan="1">250</td><td align="left" colspan="1" rowspan="1">275931.8</td><td align="left" colspan="1" rowspan="1">0.91</td><td align="left" colspan="1" rowspan="1">5.88 (5.11, 6.78)</td><td align="left" colspan="1" rowspan="1">5.72 (4.96, 6.59)</td><td align="left" colspan="1" rowspan="1">4.99 (4.32, 5.77)</td><td align="left" colspan="1" rowspan="1">12.11 (10.42, 14.07)</td></tr></tbody></table><table-wrap-foot><p>Model 1: Non-Adjusted; Model 2: Age, Sex; Model 3: Age, Sex, Income, Smoking, Regular exercise, CCI Score; Model 4: Age, Sex, Income, Smoking, Regular exercise, CCI Score, Fasting glucose, DM Duration, Insulin, OHA, CKD, Statin, BMI</p><p>IR, incidence rate; PY, person years; HR, hazard ratio; CI, confidence interval; SLD, steatotic liver disease; MASLD, metabolic dysfunction-associated steatotic liver disease; MetALD, metabolic alcohol-associated liver disease; ALD with MD, alcohol-associated liver disease with metabolic dysfunction; VH, viral hepatitis; CV, cardiovascular; HF, heart failure</p></table-wrap-foot></table-wrap><fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Impact of adjusting variables on risk of HF and CV mortality</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2222" position="float" orientation="portrait" xlink:href="12933_2024_2489_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec17"><title>Risk of all-cause mortality and liver-related mortality by alcohol consumption and FLI categories</title><p id="Par60">Table&#160;<xref rid="Tab5" ref-type="table">5</xref> presented that higher FLI associated with higher risk of all-cause and liver-related mortality. Increased alcohol consumption (&#8805;&#8201;60&#160;g/day for male and &#8805;&#8201;50&#160;g/day for female ) showed increased risk of all-cause and liver-related mortality.<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Risk of all-cause mortality and liver-related mortality by alcohol consumption and FLI categories</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">FLI</th><th align="left" rowspan="2" colspan="1">Drinking</th><th align="left" rowspan="2" colspan="1"><italic toggle="yes">N</italic></th><th align="left" rowspan="2" colspan="1">Event</th><th align="left" rowspan="2" colspan="1">Duration, PY</th><th align="left" rowspan="2" colspan="1">IR, 1000 PY</th><th align="left" colspan="4" rowspan="1">HR (95% CI)</th></tr><tr><th align="left" colspan="1" rowspan="1">Model 1</th><th align="left" colspan="1" rowspan="1">Model 2</th><th align="left" colspan="1" rowspan="1">Model 3</th><th align="left" colspan="1" rowspan="1">Model 4</th></tr></thead><tbody><tr><td align="left" colspan="10" rowspan="1"><italic toggle="yes">All-cause mortality</italic></td></tr><tr><td align="left" rowspan="4" colspan="1">&lt;&#8201;30</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">523,493</td><td align="left" colspan="1" rowspan="1">48,024</td><td align="left" colspan="1" rowspan="1">3632122.7</td><td align="left" colspan="1" rowspan="1">13.22</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">225,152</td><td align="left" colspan="1" rowspan="1">14,164</td><td align="left" colspan="1" rowspan="1">1563761.0</td><td align="left" colspan="1" rowspan="1">9.06</td><td align="left" colspan="1" rowspan="1">0.69 (0.68, 0.70)</td><td align="left" colspan="1" rowspan="1">0.85 (0.83, 0.87)</td><td align="left" colspan="1" rowspan="1">0.83 (0.82, 0.85)</td><td align="left" colspan="1" rowspan="1">0.85 (0.84, 0.87)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">33,428</td><td align="left" colspan="1" rowspan="1">2,852</td><td align="left" colspan="1" rowspan="1">229140.9</td><td align="left" colspan="1" rowspan="1">12.45</td><td align="left" colspan="1" rowspan="1">0.95 (0.91, 0.98)</td><td align="left" colspan="1" rowspan="1">1.18 (1.14, 1.23)</td><td align="left" colspan="1" rowspan="1">1.08 (1.04, 1.13)</td><td align="left" colspan="1" rowspan="1">1.06 (1.02, 1.10)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">7,581</td><td align="left" colspan="1" rowspan="1">903</td><td align="left" colspan="1" rowspan="1">51576.1</td><td align="left" colspan="1" rowspan="1">17.51</td><td align="left" colspan="1" rowspan="1">1.33 (1.24, 1.42)</td><td align="left" colspan="1" rowspan="1">1.56 (1.46, 1.66)</td><td align="left" colspan="1" rowspan="1">1.39 (1.31, 1.49)</td><td align="left" colspan="1" rowspan="1">1.31 (1.23, 1.40)</td></tr><tr><td align="left" rowspan="4" colspan="1">30&#8211;60</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">359,014</td><td align="left" colspan="1" rowspan="1">28,135</td><td align="left" colspan="1" rowspan="1">2516753.8</td><td align="left" colspan="1" rowspan="1">11.18</td><td align="left" colspan="1" rowspan="1">0.85 (0.83, 0.86)</td><td align="left" colspan="1" rowspan="1">0.85 (0.84, 0.86)</td><td align="left" colspan="1" rowspan="1">0.85 (0.84, 0.86)</td><td align="left" colspan="1" rowspan="1">1.19 (1.17, 1.21)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">234,722</td><td align="left" colspan="1" rowspan="1">13,100</td><td align="left" colspan="1" rowspan="1">1637401.0</td><td align="left" colspan="1" rowspan="1">8.00</td><td align="left" colspan="1" rowspan="1">0.61 (0.60, 0.62)</td><td align="left" colspan="1" rowspan="1">0.76 (0.75, 0.78)</td><td align="left" colspan="1" rowspan="1">0.75 (0.73, 0.76)</td><td align="left" colspan="1" rowspan="1">0.99 (0.97, 1.02)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">55,134</td><td align="left" colspan="1" rowspan="1">3,999</td><td align="left" colspan="1" rowspan="1">380674.8</td><td align="left" colspan="1" rowspan="1">10.51</td><td align="left" colspan="1" rowspan="1">0.80 (0.77, 0.83)</td><td align="left" colspan="1" rowspan="1">1.03 (1.00, 1.06)</td><td align="left" colspan="1" rowspan="1">0.96 (0.93, 0.99)</td><td align="left" colspan="1" rowspan="1">1.18 (1.14, 1.22)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">14,792</td><td align="left" colspan="1" rowspan="1">1,466</td><td align="left" colspan="1" rowspan="1">101357.2</td><td align="left" colspan="1" rowspan="1">14.46</td><td align="left" colspan="1" rowspan="1">1.10 (1.04, 1.15)</td><td align="left" colspan="1" rowspan="1">1.34 (1.27, 1.41)</td><td align="left" colspan="1" rowspan="1">1.23 (1.17, 1.30)</td><td align="left" colspan="1" rowspan="1">1.43 (1.36, 1.51)</td></tr><tr><td align="left" rowspan="4" colspan="1">&#8805;&#8201;60</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">211,722</td><td align="left" colspan="1" rowspan="1">14,888</td><td align="left" colspan="1" rowspan="1">1474920.1</td><td align="left" colspan="1" rowspan="1">10.09</td><td align="left" colspan="1" rowspan="1">0.77 (0.75, 0.78)</td><td align="left" colspan="1" rowspan="1">0.97 (0.95, 0.99)</td><td align="left" colspan="1" rowspan="1">0.97 (0.95, 0.99)</td><td align="left" colspan="1" rowspan="1">1.78 (1.74, 1.82)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">242,848</td><td align="left" colspan="1" rowspan="1">11,418</td><td align="left" colspan="1" rowspan="1">1683132.0</td><td align="left" colspan="1" rowspan="1">6.78</td><td align="left" colspan="1" rowspan="1">0.52 (0.51, 0.53)</td><td align="left" colspan="1" rowspan="1">0.88 (0.87, 0.90)</td><td align="left" colspan="1" rowspan="1">0.85 (0.83, 0.87)</td><td align="left" colspan="1" rowspan="1">1.43 (1.39, 1.46)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">92,058</td><td align="left" colspan="1" rowspan="1">5,480</td><td align="left" colspan="1" rowspan="1">635900.6</td><td align="left" colspan="1" rowspan="1">8.62</td><td align="left" colspan="1" rowspan="1">0.66 (0.64, 0.68)</td><td align="left" colspan="1" rowspan="1">1.12 (1.09, 1.15)</td><td align="left" colspan="1" rowspan="1">1.04 (1.01, 1.07)</td><td align="left" colspan="1" rowspan="1">1.63 (1.58, 1.68)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">31,577</td><td align="left" colspan="1" rowspan="1">2,567</td><td align="left" colspan="1" rowspan="1">216766.6</td><td align="left" colspan="1" rowspan="1">11.84</td><td align="left" colspan="1" rowspan="1">0.91 (0.87, 0.95)</td><td align="left" colspan="1" rowspan="1">1.48 (1.42, 1.54)</td><td align="left" colspan="1" rowspan="1">1.37 (1.31, 1.42)</td><td align="left" colspan="1" rowspan="1">2.05 (1.97, 2.14)</td></tr><tr><td align="left" colspan="10" rowspan="1"><italic toggle="yes">Liver-related mortality (K70-76)</italic></td></tr><tr><td align="left" rowspan="4" colspan="1">&lt;&#8201;30</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">523,493</td><td align="left" colspan="1" rowspan="1">501</td><td align="left" colspan="1" rowspan="1">3632122.7</td><td align="left" colspan="1" rowspan="1">0.14</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td><td align="left" colspan="1" rowspan="1">1 (Ref.)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">225,152</td><td align="left" colspan="1" rowspan="1">230</td><td align="left" colspan="1" rowspan="1">1563761.0</td><td align="left" colspan="1" rowspan="1">0.15</td><td align="left" colspan="1" rowspan="1">1.07 (0.91, 1.25)</td><td align="left" colspan="1" rowspan="1">0.95 (0.81, 1.12)</td><td align="left" colspan="1" rowspan="1">0.95 (0.81, 1.11)</td><td align="left" colspan="1" rowspan="1">0.97 (0.83, 1.14)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">33,428</td><td align="left" colspan="1" rowspan="1">77</td><td align="left" colspan="1" rowspan="1">229140.9</td><td align="left" colspan="1" rowspan="1">0.34</td><td align="left" colspan="1" rowspan="1">2.44 (1.92, 3.10)</td><td align="left" colspan="1" rowspan="1">2.10 (1.64, 2.67)</td><td align="left" colspan="1" rowspan="1">1.88 (1.47, 2.41)</td><td align="left" colspan="1" rowspan="1">1.72 (1.34, 2.19)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">7,581</td><td align="left" colspan="1" rowspan="1">37</td><td align="left" colspan="1" rowspan="1">51576.1</td><td align="left" colspan="1" rowspan="1">0.72</td><td align="left" colspan="1" rowspan="1">5.20 (3.73, 7.26)</td><td align="left" colspan="1" rowspan="1">4.20 (2.99, 5.87)</td><td align="left" colspan="1" rowspan="1">3.65 (2.60, 5.11)</td><td align="left" colspan="1" rowspan="1">3.02 (2.15, 4.23)</td></tr><tr><td align="left" rowspan="4" colspan="1">30&#8211;60</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">359,014</td><td align="left" colspan="1" rowspan="1">446</td><td align="left" colspan="1" rowspan="1">2516753.8</td><td align="left" colspan="1" rowspan="1">0.18</td><td align="left" colspan="1" rowspan="1">1.29 (1.13, 1.46)</td><td align="left" colspan="1" rowspan="1">1.21 (1.07, 1.38)</td><td align="left" colspan="1" rowspan="1">1.22 (1.07, 1.39)</td><td align="left" colspan="1" rowspan="1">3.54 (3.10, 4.05)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">234,722</td><td align="left" colspan="1" rowspan="1">336</td><td align="left" colspan="1" rowspan="1">1637401.0</td><td align="left" colspan="1" rowspan="1">0.21</td><td align="left" colspan="1" rowspan="1">1.49 (1.30, 1.71)</td><td align="left" colspan="1" rowspan="1">1.25 (1.09, 1.45)</td><td align="left" colspan="1" rowspan="1">1.25 (1.08, 1.44)</td><td align="left" colspan="1" rowspan="1">2.93 (2.52, 3.41)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">55,134</td><td align="left" colspan="1" rowspan="1">229</td><td align="left" colspan="1" rowspan="1">380674.8</td><td align="left" colspan="1" rowspan="1">0.60</td><td align="left" colspan="1" rowspan="1">4.37 (3.74, 5.11)</td><td align="left" colspan="1" rowspan="1">3.60 (3.06, 4.24)</td><td align="left" colspan="1" rowspan="1">3.33 (2.83, 3.92)</td><td align="left" colspan="1" rowspan="1">6.11 (5.17, 7.23)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">14,792</td><td align="left" colspan="1" rowspan="1">127</td><td align="left" colspan="1" rowspan="1">101357.2</td><td align="left" colspan="1" rowspan="1">1.25</td><td align="left" colspan="1" rowspan="1">9.07 (7.47, 11.02)</td><td align="left" colspan="1" rowspan="1">7.21 (5.90, 8.80)</td><td align="left" colspan="1" rowspan="1">6.45 (5.28, 7.89)</td><td align="left" colspan="1" rowspan="1">10.35 (8.45, 12.68)</td></tr><tr><td align="left" rowspan="4" colspan="1">&#8805;&#8201;60</td><td align="left" colspan="1" rowspan="1">Non</td><td align="left" colspan="1" rowspan="1">211,722</td><td align="left" colspan="1" rowspan="1">440</td><td align="left" colspan="1" rowspan="1">1474920.1</td><td align="left" colspan="1" rowspan="1">0.30</td><td align="left" colspan="1" rowspan="1">2.17 (1.91, 2.47)</td><td align="left" colspan="1" rowspan="1">2.22 (1.96, 2.53)</td><td align="left" colspan="1" rowspan="1">2.24 (1.97, 2.55)</td><td align="left" colspan="1" rowspan="1">13.90 (12.01, 16.08)</td></tr><tr><td align="left" colspan="1" rowspan="1">Mild</td><td align="left" colspan="1" rowspan="1">242,848</td><td align="left" colspan="1" rowspan="1">649</td><td align="left" colspan="1" rowspan="1">1683132.0</td><td align="left" colspan="1" rowspan="1">0.39</td><td align="left" colspan="1" rowspan="1">2.81 (2.50, 3.16)</td><td align="left" colspan="1" rowspan="1">2.70 (2.38, 3.06)</td><td align="left" colspan="1" rowspan="1">2.64 (2.32, 2.99)</td><td align="left" colspan="1" rowspan="1">11.74 (10.21, 13.50)</td></tr><tr><td align="left" colspan="1" rowspan="1">Heavy</td><td align="left" colspan="1" rowspan="1">92,058</td><td align="left" colspan="1" rowspan="1">631</td><td align="left" colspan="1" rowspan="1">635900.6</td><td align="left" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">7.27 (6.46, 8.17)</td><td align="left" colspan="1" rowspan="1">6.73 (5.93, 7.65)</td><td align="left" colspan="1" rowspan="1">6.27 (5.51, 7.13)</td><td align="left" colspan="1" rowspan="1">22.67 (19.75, 26.01)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alcoholic</td><td align="left" colspan="1" rowspan="1">31,577</td><td align="left" colspan="1" rowspan="1">409</td><td align="left" colspan="1" rowspan="1">216766.6</td><td align="left" colspan="1" rowspan="1">1.89</td><td align="left" colspan="1" rowspan="1">13.83 (12.14, 15.77)</td><td align="left" colspan="1" rowspan="1">12.47 (10.84, 14.34)</td><td align="left" colspan="1" rowspan="1">11.37 (9.87, 13.09)</td><td align="left" colspan="1" rowspan="1">37.10 (32.01, 43.01)</td></tr></tbody></table><table-wrap-foot><p>CV, cardiovascular; FLI, fatty liver index; HF, heart failure; IR incidence rate; PY, person years</p><p>Mild, 30&#160;g/day in male and &lt;&#8201;20&#160;g/day in female; Heavy, 30&#8211;60&#160;g/day in male and 20&#8211;50&#160;g/day in female;, Alcoholic, &#8805;&#8201;60&#160;g/day for male and &#8805;&#8201;50&#160;g/day for female</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec18"><title>Subgroup analysis</title><p id="Par61">Supplementary Table 4 shows the subgroup analyses of the risks of HF and CV mortality stratified by several variables. We found that SLD increased the risk of HF or CV mortality, independent of the indicated factors (P for interaction&#8201;&gt;&#8201;0.05). However, the effect of SLD on the risk of HF was influenced by factors such as age, sex, BMI, CKD, smoking status, use of HTN medication, HDL level, use of statins, regular exercise, DM duration, fasting glucose level and use of OHA. In addition, several factors, such as age, HDL-C level, regular exercise, statin and use of OHA or insulin affected the association between SLD and CV mortality.</p></sec><sec id="Sec19"><title>Sensitivity analysis</title><p id="Par62">Supplementary Table 5 exhibits the risk of HF and CV mortality according to SLD status and history of CV disease. Although participants with a history of CV disease showed a higher risk of incident HF and CV mortality compared with participants without a history of CV disease, our analysis revealed that the spectrum of SLD increased the risk of HF and CV mortality regardless of history of CV disease. (P for interaction&#8201;&gt;&#8201;0.05)</p><p id="Par63">Furthermore, when we performed competing risk analysis, as non-CV death was considered a competing risk, the SLD group showed consistently increased risk of HF, CV mortality and liver-related mortality as presented in Supplementary Table 6. Also Supplementary Tables 7 and Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref> showed the HRs for the adjusting variable.</p></sec></sec><sec id="Sec20" sec-type="discussion"><title>Discussion</title><p id="Par64">This large, representative, nationwide cohort study demonstrated that SLD, including MASLD, MetALD, and ALD with MD, was associated with an increased risk of HF and CV mortality in patients with T2DM. Furthermore, the severity of SLD, as measured by the FLI, was positively associated with the increased risk of HF and CV mortality. Interestingly, our study revealed a J-shaped association between alcohol consumption and the risk of HF.</p><p id="Par65">In terms of all-cause mortality and liver-related mortality, SLD was associated with an increased risk of mortality in patients with T2DM. Notably, viral hepatitis showed an additional effect on all-cause and liver-related mortality. Furthermore, even in all-cause mortality and liver-related mortality, alcohol consumption showed J-shaped association&#8211; mild drinker showed lower risk of mortality and heavy drinker showed increased risk of mortality compared to non-drinker.</p><p id="Par66">In the present study, we investigated the prevalence of SLD in patients with T2DM and found significant prevalence of MASLD (49.6%), MetALD (7.2%), ALD with MD (2.3%) and MASLD with VH (2.0%). The prevalence of MASLD in our study population is consistent with the findings of a recent meta-analysis conducted in East Asia, which reported a pooled prevalence of NAFLD of 52.89% (95% CI; 48.60&#8211;57.15) among individuals with T2DM [<xref ref-type="bibr" rid="CR6">6</xref>]. Because of the recent changes in definition, epidemiological data on these specific entities, especially in persons with T2DM, are limited. Furthermore, existing epidemiological studies often excluded individuals with ALD and MD who also have SLD and very heavy alcohol consumption; consequently, individuals with MASLD who also have very heavy alcohol consumption may be missed. Therefore, our study included the specific features of the MetALD and ALD with MD groups.</p><p id="Par67">Our study revealed a significant association between all SLD subtypes and a higher risk of incident HF and CV mortality in individuals with T2DM. This finding aligns with existing knowledge, as both T2DM and NAFLD are established as independent risk factors for HF and CV disease [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>]. However, research specifically examining the association between MASLD and CV events in individuals with T2DM, particularly focusing on incident HF, is limited. While a recent retrospective cohort study involving 351,068 individuals with MASLD demonstrated an increased risk of CV events [<xref ref-type="bibr" rid="CR21">21</xref>], it did not explore incident HF. Additionally, the study included only 24,166 individuals with both T2DM and MASLD, although approximately half of the patients with MASLD had T2DM [<xref ref-type="bibr" rid="CR22">22</xref>]. </p><p id="Par68">Although a few cohort studies have explored the risk of HF in patients with MASLD and T2DM, their generalizability is limited. For example, one study including 134,368 individuals with T2DM reported a positive association between NAFLD and HF mortality. However, only 1,452 individuals with NAFLD and T2DM were detected because of their reliance on ICD codes for NAFLD diagnosis, which likely underestimated the true prevalence [<xref ref-type="bibr" rid="CR16">16</xref>]. Similarly, the Kailuan cohort study observed an elevated risk of HF in patients with MASLD and T2DM compared to the no SLD group; however, only 383 individuals with MASLD and T2DM were included [<xref ref-type="bibr" rid="CR23">23</xref>]. </p><p id="Par69">Regarding the relationship between alcohol consumption and the risk of incident HF and CV mortality in patients with T2DM, a J-shaped association was observed regardless of the SLD status, as further stratified by the FLI. Across all FLI ranges, mild drinkers showed a lower risk of incident HF and CV mortality than non-drinkers. However, this risk was significantly higher in the very heavy alcohol consumption group. Notably, these findings remained consistent after excluding individuals with MASLD and VH. This aligns with a systematic review analyzing 56 cohort studies that reported that moderate alcohol consumption was associated with a decreased risk of CV mortality, whereas heavy consumption showed the opposite effect [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Although alcohol consumption is a recognized risk factor for HF, recent meta-analyses have suggested that light alcohol consumption may be associated with a lower risk of HF [<xref ref-type="bibr" rid="CR26">26</xref>]. Even in patients with SLD, mild alcohol consumption (&lt;&#8201;30&#160;g/day) was associated with a lower CV disease risk. Furthermore, when we analyzed liver-related mortality and all-cause mortality, mild-drinkers also showed a trend towards a lower risk than non-drinkers as shown in Table&#160;<xref rid="Tab5" ref-type="table">5</xref>. However, we estimated alcohol consumption based on a single health examination. Therefore, we could not distinguish between former drinkers and lifetime abstainers. It is possible that individuals who quit drinking because of health issues may have biased the results. Therefore, further research is needed to interpret the relationship between alcohol consumption and mortality.</p><p id="Par70">In the subgroup analysis, the relatively younger age group (&lt;&#8201;60 years) showed a higher magnitude of increased risk of CV mortality than older age group (&#8805;&#8201;60 years). In addition, female patients with SLD were more susceptible to incident HF than male. Moreover, patients with T2DM requiring insulin were more attributed to SLD on CV mortality. This aligns with data from nationwide cohort study, in which patient with T2DM requiring insulin was associated with a higher risk of CV mortality [<xref ref-type="bibr" rid="CR27">27</xref>]. Therefore, it can be inferred that individuals with young age, female sex, significant degree of insulin resistance and a SLD phenotype are at a higher risk of CV mortality. These observations highlight the importance of the early identification and intensive treatment of SLD, particularly in these patients.</p><p id="Par71">Our study has several strengths. To the best of our knowledge, this is the first long-term nationwide cohort study to investigate the association among new-onset HF risk, CV mortality, and SLD in patients with T2DM. Several randomized controlled trials have shown promise in reducing hepatic steatosis with emerging antidiabetic drugs, such as glucagon-like peptide-1 agonists. Therefore, identifying patients with T2DM who are at increased risk of HF and CV mortality through the lens of SLD subtypes is crucial. Furthermore, we used a comprehensive set of adjusted variables that allowed for reliable and well-supported results. In addition, to clarify the additional effect of viral hepatitis on the risk of mortality, we further analyzed the data by separating the group with MASLD and VH. We conducted a sensitivity analysis to stratify the subjects according to the FLI. We used an FLI cutoff of 30; however, when we used an FLI cutoff of 60, a similar trend in the incidence of HF and CV mortality was observed. Above all, we revealed which phenotype is at higher risk of HF and CV mortality.</p><p id="Par72">This study has several limitations. First, we used FLI rather than imaging or biopsy to define SLD. However, the FLI has been established as a reliable tool for screening patients with SLD [<xref ref-type="bibr" rid="CR28">28</xref>]. Studies have shown its accuracy in diagnosing NAFLD, with an AUC exceeding 0.8<sup>29, 30</sup> and it has been validated in the Korean population [<xref ref-type="bibr" rid="CR31">31</xref>]. Second, we could not estimate the subject&#8217;s lifetime alcohol consumption. Finally, we attempted to minimize bias through competing risk analysis and sensitivity analysis, but there might have been unmeasurable bias.</p><p id="Par73">Our study has demonstrated that SLD is an independent risk factor for new-onset HF and CV mortality in patients with T2DM especially who had younger age, female sex and significant degree of insulin resistance. Additionally, SLD severity appears to be associated with an increased risk of HF, CV mortality, all-cause mortality and liver-related mortality. Notably, regarding all-cause mortality and liver-related mortality, viral hepatitis showed additional impact on mortality. Furthermore, our study revealed that alcohol consumption has a J-shaped association with the risk of HF, CV mortality, all-cause mortality and liver-related mortality in patients with T2DM, regardless of the SLD status.</p></sec><sec id="Sec21" sec-type="supplementary-material"><title>Electronic Supplementary Material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12933_2024_2489_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>aHR</term><def><p id="Par5">Adjusted hazard ratio</p></def></def-item><def-item><term>ALD with MD</term><def><p id="Par6">Alcohol-associated liver disease with metabolic dysfunction</p></def></def-item><def-item><term>ALT</term><def><p id="Par7">Alanine aminotransferase</p></def></def-item><def-item><term>AST</term><def><p id="Par8">Aspartate aminotransferase</p></def></def-item><def-item><term>BMI</term><def><p id="Par9">Body mass index</p></def></def-item><def-item><term>CCI</term><def><p id="Par10">Charlson Comorbidity Index</p></def></def-item><def-item><term>CI</term><def><p id="Par11">Confidence interval</p></def></def-item><def-item><term>CKD</term><def><p id="Par12">Chronic kidney disease</p></def></def-item><def-item><term>CV</term><def><p id="Par13">Cardiovascular</p></def></def-item><def-item><term>eGFR</term><def><p id="Par14">Estimated glomerular filtration rate</p></def></def-item><def-item><term>FG</term><def><p id="Par15">Fasting glucose</p></def></def-item><def-item><term>FLI</term><def><p id="Par16">Fatty liver index</p></def></def-item><def-item><term>&#947;-GTP</term><def><p id="Par17">gamma-glutamyl-transferase</p></def></def-item><def-item><term>HDL-C</term><def><p id="Par18">High-density lipoprotein cholesterol</p></def></def-item><def-item><term>HF</term><def><p id="Par19">Heart failure</p></def></def-item><def-item><term>HR</term><def><p id="Par20">Hazard ratio</p></def></def-item><def-item><term>HTN</term><def><p id="Par21">Hypertension</p></def></def-item><def-item><term>LDL-C</term><def><p id="Par22">Low-density lipoprotein cholesterol</p></def></def-item><def-item><term>MASLD</term><def><p id="Par23">Metabolic dysfunction-associated steatotic liver disease</p></def></def-item><def-item><term>MetALD</term><def><p id="Par24">Metabolic alcohol-associated liver disease</p></def></def-item><def-item><term>NAFLD</term><def><p id="Par25">Nonalcoholic fatty liver disease</p></def></def-item><def-item><term>NHIS</term><def><p id="Par26">National Health Insurance Service</p></def></def-item><def-item><term>OAC</term><def><p id="Par27">Oral anticoagulant</p></def></def-item><def-item><term>OHA</term><def><p id="Par28">Oral hypoglycemic agent</p></def></def-item><def-item><term>Other</term><def><p id="Par29">Other co-existing liver diseases</p></def></def-item><def-item><term>SLD</term><def><p id="Par30">Steatotic liver disease</p></def></def-item><def-item><term>TG</term><def><p id="Par31">Triglycerides</p></def></def-item><def-item><term>T2DM</term><def><p id="Par32">Type 2 diabetes mellitus</p></def></def-item><def-item><term>VH</term><def><p id="Par33">Viral hepatitis</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Rosa Oh and Gyuri Kim have contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Author contributions: J.H.K. and K.H conceived the study. K. H and J. H. K. designed the study. K.L. collected and analyzed the data. R.O. and G.K interpreted the results and wrote the manuscript. R.O, G.K, K.H and J.H.K. edited the manuscript and contributed to discussion. All authors contributed to the discussion and reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>None.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar6"><title>Ethics approval and consent to participate</title><p id="Par74">The Institutional Review Board of the Samsung Medical Center approved this study (IRB 2024-03-104). Written informed consent was waived because all data was de-identified.</p></notes><notes id="FPar7"><title>Consent for publication</title><p id="Par75">Written informed consent was waived because all data was de-identified.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par76">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>MAB</given-names></name><name name-style="western"><surname>Hashim</surname><given-names>MJ</given-names></name><name name-style="western"><surname>King</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends</article-title><source>J Epidemiol Glob Health</source><year>2020</year><volume>10</volume><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.2991/jegh.k.191028.001</pub-id><pub-id pub-id-type="pmid">32175717</pub-id><pub-id pub-id-type="pmcid">PMC7310804</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Khan MAB, Hashim MJ, King JK, et al. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10:107&#8211;11.<pub-id pub-id-type="pmid">32175717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2991/jegh.k.191028.001</pub-id><pub-id pub-id-type="pmcid">PMC7310804</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeedi</surname><given-names>P</given-names></name><name name-style="western"><surname>Petersohn</surname><given-names>I</given-names></name><name name-style="western"><surname>Salpea</surname><given-names>P</given-names></name><etal/></person-group><article-title>Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition</article-title><source>Diabetes Res Clin Pract</source><year>2019</year><volume>157</volume><fpage>107843</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2019.107843</pub-id><pub-id pub-id-type="pmid">31518657</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157: 107843.<pub-id pub-id-type="pmid">31518657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2019.107843</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roden</surname><given-names>M</given-names></name><name name-style="western"><surname>Shulman</surname><given-names>GI</given-names></name></person-group><article-title>The integrative biology of type 2 diabetes</article-title><source>Nature</source><year>2019</year><volume>576</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1797-8</pub-id><pub-id pub-id-type="pmid">31802013</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576:51&#8211;60.<pub-id pub-id-type="pmid">31802013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-019-1797-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosmas</surname><given-names>CE</given-names></name><name name-style="western"><surname>Bousvarou</surname><given-names>MD</given-names></name><name name-style="western"><surname>Kostara</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Insulin resistance and cardiovascular disease</article-title><source>J Int Med Res</source><year>2023</year><volume>51</volume><fpage>3000605231164548</fpage><pub-id pub-id-type="doi">10.1177/03000605231164548</pub-id><pub-id pub-id-type="pmid">36994866</pub-id><pub-id pub-id-type="pmcid">PMC10069006</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Kosmas CE, Bousvarou MD, Kostara CE, et al. Insulin resistance and cardiovascular disease. J Int Med Res. 2023;51:3000605231164548.<pub-id pub-id-type="pmid">36994866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/03000605231164548</pub-id><pub-id pub-id-type="pmcid">PMC10069006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Einarson</surname><given-names>TR</given-names></name><name name-style="western"><surname>Acs</surname><given-names>A</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>C</given-names></name><etal/></person-group><article-title>Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007&#8211;2017</article-title><source>Cardiovasc Diabetol</source><year>2018</year><volume>17</volume><fpage>83</fpage><pub-id pub-id-type="doi">10.1186/s12933-018-0728-6</pub-id><pub-id pub-id-type="pmid">29884191</pub-id><pub-id pub-id-type="pmcid">PMC5994068</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007&#8211;2017. Cardiovasc Diabetol. 2018;17:83.<pub-id pub-id-type="pmid">29884191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-018-0728-6</pub-id><pub-id pub-id-type="pmcid">PMC5994068</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younossi</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Golabi</surname><given-names>P</given-names></name><name name-style="western"><surname>de Avila</surname><given-names>L</given-names></name><etal/></person-group><article-title>The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis</article-title><source>J Hepatol</source><year>2019</year><volume>71</volume><fpage>793</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.06.021</pub-id><pub-id pub-id-type="pmid">31279902</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71:793&#8211;801.<pub-id pub-id-type="pmid">31279902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2019.06.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990&#8211;2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789&#8211;1858.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)32279-7</pub-id><pub-id pub-id-type="pmcid">PMC6227754</pub-id><pub-id pub-id-type="pmid">30496104</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urbich</surname><given-names>M</given-names></name><name name-style="western"><surname>Globe</surname><given-names>G</given-names></name><name name-style="western"><surname>Pantiri</surname><given-names>K</given-names></name><etal/></person-group><article-title>A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014&#8211;2020)</article-title><source>Pharmacoeconomics</source><year>2020</year><volume>38</volume><fpage>1219</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.1007/s40273-020-00952-0</pub-id><pub-id pub-id-type="pmid">32812149</pub-id><pub-id pub-id-type="pmcid">PMC7546989</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Urbich M, Globe G, Pantiri K, et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014&#8211;2020). Pharmacoeconomics. 2020;38:1219&#8211;36.<pub-id pub-id-type="pmid">32812149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40273-020-00952-0</pub-id><pub-id pub-id-type="pmcid">PMC7546989</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahim</surname><given-names>B</given-names></name><name name-style="western"><surname>Kapelios</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Savarese</surname><given-names>G</given-names></name><etal/></person-group><article-title>Global Public Health Burden of Heart Failure: An Updated Review</article-title><source>Card Fail Rev</source><year>2023</year><volume>9</volume><fpage>e11</fpage><pub-id pub-id-type="doi">10.15420/cfr.2023.05</pub-id><pub-id pub-id-type="pmid">37547123</pub-id><pub-id pub-id-type="pmcid">PMC10398425</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Shahim B, Kapelios CJ, Savarese G, et al. Global Public Health Burden of Heart Failure: An Updated Review. Card Fail Rev. 2023;9: e11.<pub-id pub-id-type="pmid">37547123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15420/cfr.2023.05</pub-id><pub-id pub-id-type="pmcid">PMC10398425</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rinella</surname><given-names>ME</given-names></name><name name-style="western"><surname>Lazarus</surname><given-names>JV</given-names></name><name name-style="western"><surname>Ratziu</surname><given-names>V</given-names></name><etal/></person-group><article-title>A multisociety Delphi consensus statement on new fatty liver disease nomenclature</article-title><source>J Hepatol</source><year>2023</year><volume>79</volume><fpage>1542</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.06.003</pub-id><pub-id pub-id-type="pmid">37364790</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542&#8211;56.<pub-id pub-id-type="pmid">37364790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2023.06.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>MK</given-names></name><name name-style="western"><surname>Han</surname><given-names>K</given-names></name><name name-style="western"><surname>Cho</surname><given-names>JH</given-names></name><etal/></person-group><article-title>A model to predict risk of stroke in middle-aged adults with type 2 diabetes generated from a nationwide population-based cohort study in Korea</article-title><source>Diabetes Res Clin Pract</source><year>2020</year><volume>163</volume><fpage>108157</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2020.108157</pub-id><pub-id pub-id-type="pmid">32333968</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kim MK, Han K, Cho JH, et al. A model to predict risk of stroke in middle-aged adults with type 2 diabetes generated from a nationwide population-based cohort study in Korea. Diabetes Res Clin Pract. 2020;163: 108157.<pub-id pub-id-type="pmid">32333968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2020.108157</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koo</surname><given-names>BK</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>Prediction of Coronary Heart Disease Risk in Korean Patients with Diabetes Mellitus</article-title><source>J Lipid Atheroscler</source><year>2018</year><volume>7</volume><fpage>110</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.12997/jla.2018.7.2.110</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Koo BK, Oh S, Kim YJ, et al. Prediction of Coronary Heart Disease Risk in Korean Patients with Diabetes Mellitus. J Lipid Atheroscler. 2018;7:110&#8211;21.</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheol Seong</surname><given-names>S</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YY</given-names></name><name name-style="western"><surname>Khang</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea</article-title><source>Int J Epidemiol</source><year>2017</year><volume>46</volume><fpage>799</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">27794523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyw253</pub-id><pub-id pub-id-type="pmcid">PMC5837262</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Cheol Seong S, Kim YY, Khang YH, et al. Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017;46:799&#8211;800.<pub-id pub-id-type="pmid">27794523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ije/dyw253</pub-id><pub-id pub-id-type="pmcid">PMC5837262</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedogni</surname><given-names>G</given-names></name><name name-style="western"><surname>Bellentani</surname><given-names>S</given-names></name><name name-style="western"><surname>Miglioli</surname><given-names>L</given-names></name><etal/></person-group><article-title>The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population</article-title><source>BMC Gastroenterol</source><year>2006</year><volume>6</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/1471-230X-6-33</pub-id><pub-id pub-id-type="pmid">17081293</pub-id><pub-id pub-id-type="pmcid">PMC1636651</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.<pub-id pub-id-type="pmid">17081293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-230X-6-33</pub-id><pub-id pub-id-type="pmcid">PMC1636651</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Jung</surname><given-names>GC</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population</article-title><source>Diagnostics (Basel)</source><year>2021</year><volume>11</volume><fpage>2233</fpage><pub-id pub-id-type="doi">10.3390/diagnostics11122233</pub-id><pub-id pub-id-type="pmid">34943469</pub-id><pub-id pub-id-type="pmcid">PMC8699943</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Cho EJ, Jung GC, Kwak MS, et al. Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population. Diagnostics (Basel). 2021;11:2233.<pub-id pub-id-type="pmid">34943469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics11122233</pub-id><pub-id pub-id-type="pmcid">PMC8699943</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wild</surname><given-names>SH</given-names></name><name name-style="western"><surname>Walker</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Morling</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission</article-title><source>Diabetes Care</source><year>2018</year><volume>41</volume><fpage>341</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.2337/dc17-1590</pub-id><pub-id pub-id-type="pmid">29167212</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wild SH, Walker JJ, Morling JR, et al. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes Care. 2018;41:341&#8211;7.<pub-id pub-id-type="pmid">29167212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc17-1590</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinn</surname><given-names>DH</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study</article-title><source>J Gastroenterol Hepatol</source><year>2020</year><volume>35</volume><fpage>833</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1111/jgh.14856</pub-id><pub-id pub-id-type="pmid">31512278</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Sinn DH, Kang D, Chang Y, et al. Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. J Gastroenterol Hepatol. 2020;35:833&#8211;9.<pub-id pub-id-type="pmid">31512278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgh.14856</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BS</given-names></name><etal/></person-group><article-title>The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study</article-title><source>Cardiovasc Diabetol</source><year>2022</year><volume>21</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s12933-022-01483-y</pub-id><pub-id pub-id-type="pmid">35429980</pub-id><pub-id pub-id-type="pmcid">PMC9013458</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Park J, Kim G, Kim BS, et al. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol. 2022;21:53.<pub-id pub-id-type="pmid">35429980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-022-01483-y</pub-id><pub-id pub-id-type="pmcid">PMC9013458</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>CH</given-names></name><name name-style="western"><surname>Han</surname><given-names>KD</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name><etal/></person-group><article-title>The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study</article-title><source>Front Endocrinol (Lausanne)</source><year>2021</year><volume>12</volume><fpage>638615</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.638615</pub-id><pub-id pub-id-type="pmid">33776934</pub-id><pub-id pub-id-type="pmcid">PMC7996574</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Lee CH, Han KD, Kim DH, et al. The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study. Front Endocrinol (Lausanne). 2021;12: 638615.<pub-id pub-id-type="pmid">33776934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2021.638615</pub-id><pub-id pub-id-type="pmcid">PMC7996574</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 2023;44:2544&#8211;2556.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehad260</pub-id><pub-id pub-id-type="pmcid">PMC10361012</pub-id><pub-id pub-id-type="pmid">37247330</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>JH</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study</article-title><source>EClinicalMedicine</source><year>2023</year><volume>65</volume><fpage>102292</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.102292</pub-id><pub-id pub-id-type="pmid">37954905</pub-id><pub-id pub-id-type="pmcid">PMC10632413</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Moon JH, Jeong S, Jang H, et al. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinicalMedicine. 2023;65: 102292.<pub-id pub-id-type="pmid">37954905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2023.102292</pub-id><pub-id pub-id-type="pmcid">PMC10632413</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Muthiah M, Ng CH, Chan KE, et al. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis. Ann Hepatol 2023;28:100762.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.aohep.2022.100762</pub-id><pub-id pub-id-type="pmid">36182031</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study</article-title><source>Diabetol Metab Syndr</source><year>2023</year><volume>15</volume><fpage>137</fpage><pub-id pub-id-type="doi">10.1186/s13098-023-01102-0</pub-id><pub-id pub-id-type="pmid">37355613</pub-id><pub-id pub-id-type="pmcid">PMC10290295</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Wei Z, Huang Z, Song Z, et al. Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study. Diabetol Metab Syndr. 2023;15:137.<pub-id pub-id-type="pmid">37355613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13098-023-01102-0</pub-id><pub-id pub-id-type="pmcid">PMC10290295</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krittanawong</surname><given-names>C</given-names></name><name name-style="western"><surname>Isath</surname><given-names>A</given-names></name><name name-style="western"><surname>Rosenson</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Alcohol Consumption and Cardiovascular Health</article-title><source>Am J Med</source><year>2022</year><volume>135</volume><issue>1213&#8211;1230</issue><fpage>e3</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2022.04.021</pub-id><pub-id pub-id-type="pmcid">PMC9529807</pub-id><pub-id pub-id-type="pmid">35580715</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Krittanawong C, Isath A, Rosenson RS, et al. Alcohol Consumption and Cardiovascular Health. Am J Med. 2022;135(1213&#8211;1230): e3.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2022.04.021</pub-id><pub-id pub-id-type="pmcid">PMC9529807</pub-id><pub-id pub-id-type="pmid">35580715</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name><name name-style="western"><surname>O'Neill</surname><given-names>D</given-names></name><name name-style="western"><surname>Bell</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association of alcohol consumption with morbidity and mortality in patients with cardiovascular disease: original data and meta-analysis of 48,423 men and women</article-title><source>BMC Med</source><year>2021</year><volume>19</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.1186/s12916-021-02040-2</pub-id><pub-id pub-id-type="pmid">34311738</pub-id><pub-id pub-id-type="pmcid">PMC8314518</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Ding C, O&#8217;Neill D, Bell S, et al. Association of alcohol consumption with morbidity and mortality in patients with cardiovascular disease: original data and meta-analysis of 48,423 men and women. BMC Med. 2021;19:167.<pub-id pub-id-type="pmid">34311738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-021-02040-2</pub-id><pub-id pub-id-type="pmcid">PMC8314518</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsson</surname><given-names>SC</given-names></name><name name-style="western"><surname>Wallin</surname><given-names>A</given-names></name><name name-style="western"><surname>Wolk</surname><given-names>A</given-names></name></person-group><article-title>Alcohol consumption and risk of heart failure: Meta-analysis of 13 prospective studies</article-title><source>Clin Nutr</source><year>2018</year><volume>37</volume><fpage>1247</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2017.05.007</pub-id><pub-id pub-id-type="pmid">28554815</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Larsson SC, Wallin A, Wolk A. Alcohol consumption and risk of heart failure: Meta-analysis of 13 prospective studies. Clin Nutr. 2018;37:1247&#8211;51.<pub-id pub-id-type="pmid">28554815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clnu.2017.05.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>R</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name></person-group><article-title>Sex differences in cardiovascular and all-cause mortality in nonalcoholic fatty liver disease in the US population</article-title><source>Nutr Metab Cardiovasc Dis</source><year>2023</year><volume>33</volume><fpage>1349</fpage><lpage>1357</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2023.03.003</pub-id><pub-id pub-id-type="pmid">37156665</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Ren R, Zheng Y. Sex differences in cardiovascular and all-cause mortality in nonalcoholic fatty liver disease in the US population. Nutr Metab Cardiovasc Dis. 2023;33:1349&#8211;57.<pub-id pub-id-type="pmid">37156665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.numecd.2023.03.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biciusca</surname><given-names>T</given-names></name><name name-style="western"><surname>Stan</surname><given-names>SI</given-names></name><name name-style="western"><surname>Balteanu</surname><given-names>MA</given-names></name><etal/></person-group><article-title>The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review</article-title><source>Diagnostics (Basel)</source><year>2023</year><volume>13</volume><fpage>3316</fpage><pub-id pub-id-type="doi">10.3390/diagnostics13213316</pub-id><pub-id pub-id-type="pmid">37958212</pub-id><pub-id pub-id-type="pmcid">PMC10649095</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Biciusca T, Stan SI, Balteanu MA, et al. The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review. Diagnostics (Basel). 2023;13:3316.<pub-id pub-id-type="pmid">37958212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics13213316</pub-id><pub-id pub-id-type="pmcid">PMC10649095</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>LD</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JF</given-names></name><name name-style="western"><surname>Chen</surname><given-names>QS</given-names></name><etal/></person-group><article-title>Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome</article-title><source>Chin Med J (Engl)</source><year>2019</year><volume>132</volume><fpage>2670</fpage><lpage>2676</lpage><pub-id pub-id-type="doi">10.1097/CM9.0000000000000503</pub-id><pub-id pub-id-type="pmid">31765354</pub-id><pub-id pub-id-type="pmcid">PMC6940109</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Chen LD, Huang JF, Chen QS, et al. Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome. Chin Med J (Engl). 2019;132:2670&#8211;6.<pub-id pub-id-type="pmid">31765354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000000503</pub-id><pub-id pub-id-type="pmcid">PMC6940109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mertens</surname><given-names>J</given-names></name><name name-style="western"><surname>Weyler</surname><given-names>J</given-names></name><name name-style="western"><surname>Dirinck</surname><given-names>E</given-names></name><etal/></person-group><article-title>Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes</article-title><source>JHEP Rep</source><year>2023</year><volume>5</volume><fpage>100753</fpage><pub-id pub-id-type="doi">10.1016/j.jhepr.2023.100753</pub-id><pub-id pub-id-type="pmid">37274774</pub-id><pub-id pub-id-type="pmcid">PMC10232726</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Mertens J, Weyler J, Dirinck E, et al. Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes. JHEP Rep. 2023;5: 100753.<pub-id pub-id-type="pmid">37274774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhepr.2023.100753</pub-id><pub-id pub-id-type="pmcid">PMC10232726</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HN</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Choi</surname><given-names>HG</given-names></name><etal/></person-group><article-title>CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease</article-title><source>BMC Gastroenterol</source><year>2023</year><volume>23</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s12876-023-02717-3</pub-id><pub-id pub-id-type="pmid">36932382</pub-id><pub-id pub-id-type="pmcid">PMC10022198</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Kim HN, Jeon HJ, Choi HG, et al. CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease. BMC Gastroenterol. 2023;23:77.<pub-id pub-id-type="pmid">36932382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12876-023-02717-3</pub-id><pub-id pub-id-type="pmcid">PMC10022198</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>